CCB2-1

JANUARY 2015 VOLUME 2, NUMBER 1

NEWS DIGEST

IN THIS ISSUENEWS DIGEST ...................1■ China needs to improve PCI accessibility■ CFDA amends pravastatin sodium

instruction■ China to release drug price control COMPANY FOCUS ............3■ Pfizer and Anzhen Hospital to set up

cardiovascular big data center■ Google Project glass used in operation

demonstration ■ Lepu Medical to increase stakes in

Qinming Medical■ Trials show positive results for

OrbusNeich’s stent■ MicroPort Castor selected as key project

of national programHOSPITAL FOCUS ............5■ Anzhen Hospital cooperates with San

Donato Group■ Infantile myxoma operated Xijing Hospital■ Zhejiang No. 2 Hospital performs

“Parachute” surgery■ 3D printing used in left atrial appendage

closure in Shanghai CLINIAL PRACTICE ........6■ Researchers report rare giant blood cyst

from bicuspid aortic valve■ Study shows admission useful in

predicting short-term outcomes of STEMI patients

■ Study shows the association between NC and early stage atherosclerosis

■ Research shows M2.5 concentration was associated with IHD morbidity and mortality

REGULATORY REVIEW ..8■ Chinese Expert Consensus for Diagnosis and

Treatment of Syncope: 2014 Updated Version■ Registration of imported vascular stents in

SFDA, 2013 & 2014MARKET REPORT..........10■ China cardiovascular mortality on the rise POC PROFILE ..................11■ Peking University First Hospital■ Peking University People’s Hospital■ West China HospitalKOL PROFILE ..................14■ Huo Yong ■ Hu Dayi ■ Huang DejiaMARKET DATA ................17■ Ranking of cardiologists in Shanghai ■ Medical insuarance for cardiac products

in China■ Top 100 hospitals by RFCA procedure

volume in China (2013)

China needs to improve PCI accessibilityDespite the fast growth of percutaneous coronary interventinon (PCI) procedure volumes over the recent years, China needs to give more acute myocardial infarction patients access to PCI.

The national PCI registry showed that the only 30% of acute STEMI patients recieved PCI treatment within 12 hours after the onset, compared with 88% in the United States.

“It is estimated that on China’s mainland, less than 5% of STEMI patients can receive early-stage revascularization,” said Huo Yong, the leader of cardiovascular disease diagnosis and treatment technology management expert team under the National Health and Family Planning Commission.

He said that direct PCI should be applied in STEMI patients in some grade two hospitals and county hospitals. This can reduce the imbalance of PCIs in China’s hospitals. According to the national PCI registry, one third of the PCI procedures were conducted in 5% of the hospitals, while 5% of PCI procedures in one third of the hospitals.

On the other hand, about 80% of the patients in China received PCI due to acute coronary syndromes, 3/4 of whom suffered unstable angina. These patients have a lower risk and many of them do not need to take PCI, so the reasonable use of PCI is also a challenging task in China, according to Huo.

Furthermore, China’s cardiologists should pay more attention to cardiac rehabilitation and second prevention, Huo said.

In 2013, over 3,000 physicians in 1,137 hospitals performed 454,505 PCI procedures, compared with 388,836 in 2012 and 332,992 in 2011. And the mortality rate was 0.26% in 2013.

C a r d i o v a s c u l a r

.2.China Cardiovascular BusinessCCB

VOLUME 2, NUMBER 1 JANUARY 2015

China Cardiovascular Business™

FOUNDED IN JANUARY 2013Published monthly by

Transmedia

PublisherFrank Li [Fukang]

Editor-in-ChiefKarl Zhong

Editorial PanelKevin Qiu, Ben Liu

Graphics & Lay-outLily Su

Operation ManagerHe Lan

CONDITIONS OF SALE

[©2015 Transmedia (Shanghai) Data Technology Co., Ld.]

EDITORIAL OFFICE

Suite 2002, No.168 Yude Rd., Xuhui District, Shanghai 200030 P.R.C.

Annual Subscription Rates:China (12 issues/year, e-copy): RMB 9,600Overseas (12 issues/year, e-copy): USD 1,530

Subscription inquiry: Tel: (8621)33682001E-mail: [email protected]: www.cardiochina.com

SUBSCRIPTIONS

China Cardiovascular BusinessTM is sold on the following conditions: 1. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocop-ying, recording, or otherwise without the prior permission of the Publisher. 2. An order for additional copies at reduced rates constitutes an undertaking by the subscriber that such copies will not be exported or distributed so as to avoid taking full price subscriptions elsewhere.

All information published in this monthly e-newsletter is believed to be truthful and accu-rate. However, the publisher assumes no respon-sibility and shall have no liability whatsoever for error, including without limitation, typographical error or omissions in the publication.

China Cardiovascular Business

Subscription Order Form

Annual Subscription Rates

□ China:RMB 9,600 for 12 issues/year □ Overseas: US$$1,530 for 12 issues/year*Subscription starts upon receipt of payment

Subscriber Name (Mr/Ms)______________ Job Title____________

Company Name [公司名称]________________________________

Postal Address [邮编地址]_________________________________

Phone______________________ Fax________________________

E-mails (limited to 3 recipients) ①___________________________

②________________________③___________________________

Payment Instructions[for overseas payers]

Payment by telegraphic transfer to:

Beneficiary : [please write the name in full and exactly as

below]

Transmedia Shanghai Ltd.

Bank Name : BANK OF CHINA, SHANGHAI GRAND

GATEWAY SUB-BRANCH

SWIFT CODE : BKCH CN BJ 30

A/C Number : 453366577528

* Please complete and e-mail this form back to [email protected].

* 请填妥订单e-mail至[email protected].

付款方式

(中国境内客户)

电汇付款至：

户名：上海传科信息技术有限公司

开户行：中国银行上海市港汇广场支行

账号： 453366577528

China Cardiovascular Business.3.


CCB

CFDA amends pravastatin sodium instruction

China Food and Drug Administration (CFDA) announced on November 27 ordering that the instructions of pravastatin sodium tablet and capsule shall be amended.

Accoding to the annoucment, the following instructions will be added: “There is the lack of sufficient evidence to prove that any HMG CoA reductase inhibitors will not increase new diabetes risk on susceptible people. It is suggested that clinical manifestations and biochemical indexes related to glucose metabolic disorder should be monitored before and during treatment with statins.”

Pravastatin sodium increases rate at which body removes cholesterol from blood and reduces production of cholesterol in body by inhibiting enzyme that catalyzes early rate-limiting step in cholesterol synthesis.

CFDA asked the manufacturers to amend the instructions within the 6 months after the annoucent was issued.

China to release drug price control China plans to scrap retail price caps on all drugs as early as the start of next year, according to state media.

The National Development and Reform Commission, China’s planning agency, has prepared a draft law for review

by the industry and could lift the caps as early as Jan. 1.

The draft rules, which were sent to eight industry bodies seeking feedback, propose to “cancel government-set prices on drugs, and through insurance price controls and the tendering process, allow the actual transaction price of drugs to be set by market competition,” the newspaper said.

Prices would be set by a combination of health insurance departments, existing tendering processes and multi-stakeholder negotiations, it said.

The caps, however, play only a limited role in the government’s price control regime, analysts said, with around two-thirds of drugs still sold in China’s vast hospital network where prices are kept low through a tendering system.

The full removal of caps should ease price pressures on both domestic and international pharmaceutical firms hoping to tap a healthcare market that McKinsey & Co estimates will grow to $1 trillion by 2020, nearly triple its size in 2011.

China removed price caps on a limited number of drugs in April after criticism that its controls had caused shortages of a number of critical drugs used by millions of patients to treat hyperthyroidism and other ailments.

COMPANY FOCUSCOMPANY FOCUSPfizer and Anzhen Hospital to set up cardiovascular big data centerPfizer and Beijing Anzhen Hospital Affiliated to Capital Medical University, China’s top cardiovascular hospital, have signed an agreement to set up the cardiovascular big data center, the hospital announced.

The agreement lasts for five years, during which the two sides will jointly establish Anzhen-Pfizer Cardiovascular Big Data Center.

The center is about to launch a series of data mining and analysis project, including clinical safety evaluation of commonly used cardiovascular drugs, building the model of predicting the risk of cardiovascular diseases, monitoring of cardiovascular patients hospitalization and death, cardiovascular medical quality assessment and

feedback system, cost benefit analysis of cardiovascular disease diagnosis and treatment, etc. The center will organize activities concerning big data technology research and development and promote the domestic and international medical exchange of the large data.

“Based on the medical data of 4.7 million Beijing residents, we plan to create the interface between cardiovascular disease database and the medical management information, medical insurance information of the Beijing public health information center,” said Professor Ma Changsheng, Director of Cardiology Department of Anzhen Hospital. “We will gradually expand the data sources and conduct the application research on the big data platform.”

The two sides did not disclose the investments which will be placed into the project.

China Cardiovascular Business .4.


CCB

Google Project glass used in operation demonstration

The Google project glass was used in an operataion demonstration in the Second Affiliated Hospital of Zhejiang University School of Medicine, a top hospital in economically developed Zhejiang province in China.

The hospital’s department of cardiology recently held a pacemaker-implanted technique demonstration and exchange meeting, which attracted doctors around Zhejiang province.

Dr. Xiang Meixiang, Vice Secretary of SAHZU Party Committee, delivered a lecture on axillary venipuncture and capsule active electrode and demonstrated the operation.

The Google project glass was used in such a demonstration for the first time in Zhejiang.

Released by Google on April 5 this year, the glass can “expand the reality”, which means that doctors who wear the glass can broadcast the live show to the medical students. Also, the operation can be rebroadcasted and recorded at the same time.

Although it still has some limits such as time delay, the application of glass facilitates teaching and academic exchanges to a great extent, the hospital’s announcement said.

Lepu Medical to increase stakes in Qinming Medical

Lepu Medical announced on Nov. 15 that it plans to acquire 51% stakes in Xindonggang Pharma for RMB 576.3 million.

Xindonggang is one of the largest Statins APIs manufacturers in the world, whose customers include 11 of the 15 world’s leading generic drugs manufacturers. Xindonggang is also one of the four domestic companies which have obtained production approval for Atorvastatin preparations.

Atorvastatin is a member of the drug class known as statins, which are used primarily for lowering blood cholesterol and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.

As Xindonggang has a big say in the Statins APIs market, it will show an advantage in the market of Atorvastatin preparations, Lepu Medical said.

Pfizer’s Lipitor sales dropped sharply after 2012 when generic Atorvastatin preparations were launched into the market.

This deal will enable Lepu to expand its business from the cardiac medical devices to the cardiac drugs sector. And Lepu said that it can integrate the sales network of the both sides to increase sales efficicency.

Trials show positive results for OrbusNeich’s stentLatest data presented on the COMBO Dual Therapy Stent provides further evidence to support the long-term safety and efficacy of the stent in the treatment of coronary artery disease, OrbusNeich announced.

The COMBO Dual Therapy Stent is the first dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the proven Pro-Healing Technology with an abluminal sirolimus drug elution delivered from a bioresorbable polymer that is completely dissipated within 90 days.

The latest results demonstrate the healing benefits of the COMBO Stent, with data supporting early stent coverage and control of neo-intimal proliferation.

Key findings from the EGO COMBO and REMEDEE First in Man (FIM) trials were presented on October 16th, at the 35th Congresso Nazionale della Societa’ Italiana di Cardiologia Invasiva (GISE) conference in Genoa, Italy by Prof. Giuseppe De Luca, of the Eastern Piedmont University in Novara, Italy.

“Clinical data gathered from the trials to date is very encouraging, particularly around the unique 24month neointima regression phenomenon,” said Prof. De Luca. “This new data validates what we have seen in clinical practice and illustrates the COMBO Stent’s ability to deliver long-term true vessel healing.”

Prof. De Luca, Co-Principal Investigator of the REDUCE trial, also announced the initiation of this multicenter trial designed to evaluate the potential for shorter-term dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients. REDUCE will for the first time evaluate



CCB

HOSPITAL FOCUSHOSPITAL FOCUSAnzhen Hospital cooperates with San Donato GroupBeijing Anzhen Hospital Affiliated to Capital Medical University recently signed the cardiovascular disease research cooperation agreement with San Donato Group of Italy.

Under the agreement, the two sides will be jointly committed to the cultivation of the young physician and the research of new cardiovascular disease treatment technology.

The two sides started the earlist exchanges in the 1990s.

Wei Yongxiang director of the hospital was among the Chinese delegation to Italy, led by Premier Li Keqiang. This is the only cooperative project in the healthcare sector signed during the premier’s trip to Italy.

Infantile myxoma operated Xijing HospitalSurgeons at Xijing Hospital’s cardiac surgery department conducted a successful surgery on a one-month-old premature child (born at 7 months in the womb) of cardiac

myxoma combined with congenital heart disease, Xijing Hospital announced on November 28.

Examinations showed that the tumor was located near the tricuspid valve, and may cause acute tricuspid infarction at any time. Myxoma is easy to fall off, which may easily cause pulmonary infarction blood vessels or metastasis.

The department discussed many times and decided to conduct three procedures: myxoma excision, auricular septal defect repair and ligation of patent ductus arteriosis.

Doctor Gu Chunhu and other doctors spent one hour and 48 minutes completing the surgery. A 2cm myxoma was removed and congenital heart disease was treated. The baby recovered after ICU treatment.

Myxoma is a common cardiac tumor for adults, but rarely seen in infants. Only 5 infantile myxoma cases have been reported in the world. The first infantile myxoma was conducted in U.S.A. in 1965.

Zhejiang No. 2 Hospital performs first

the safety of shorter (three months) DAPT in ACS patients with the COMBO Stent across centers in Europe and Asia. “I believe that the unique EPC technology featured on the COMBO Stent may safely enable us to reduce the duration of DAPT and, as a result, decrease the risk of bleeding and ensure high compliance among patients,” said Prof. De Luca.

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases.

MicroPort Castor selected as key project of national programCastor Thoracic Branch Stent-Graft System, an endovascular device developed by MicroPort Endovascular (Shanghai) Co., was successfully selected as one project of the National Key Technology R&D Program for China’s 12th Five-Year Plan in November.

Compared with other branch stent-grafts under

development, Castor has less endoleak and better branch artery patency. It also features kink-free outer sheath, arch-passing ability, soft membrane as well as soft cap with branch stent cramped in.

During the past decade, an increasingly more people suffer from thoracic dissection in China. Dissection involving left subclavian artery is currently a relative contraindication for endovascular treatment. In that case, the development of Castor is a crucial milestone in treatment of challenging aortic arch disease.

MicroPort has carried out clinical trials for Castor, which is the world’s first large-scaled and multi-centered clinical study for branched thoracic stent graft. Its clinical efficacy has gained recognitions from domestic medical professionals.

MicroPort Endovascular (Shanghai) Co. is a subsidiary of Shanghai MicroPort Medical (Group) Co., a medical device company with business focusing on innovating, manufacturing, and marketing medical devices globally.



CCB

CLINICAL PRACTICECLINICAL PRACTICE

“Parachute” surgery in ZhejiangThe cardiovascular team of the Second Affiliated Hospital of Zhejiang University School of Medicine performed the “parachute” minimally invasive surgery on patients who suffered from ventricular aneurysm.

Led by the hospital’s President WangJian’an, this kind of operation was done for the first time in Zhejiang Province.

Mr. Li, a 35 year-old man working at a mold factory in Wenling, suffered from myocardial infarction half a year ago. After assessment and discussion, doctors decided to adopted the “parachute” surgery by which the patient is installed a “parachute-like” isolation device in his left ventricle. This device will separate the abnormally-shrinking room wall, reducing the volume of left ventricle and improving the syndrome and cardiac function.

This “parachute” is a frame made up by 16 hair-like supports. Wang’s team employed minimally invasive technique to put the “parachute” into the tip of the patient’s left ventricle through his arteries.

There were two other patients who was performed the same operation on the same day, one at the age of 79, another 77. It was said that the “parachute” surgery, which

enjoys a domestic leading position, is new in Europe and America. The heart center of SAHZU is one of few centers in the world which can perform this surgery.

3D printing used in left atrial appendage closure in Shanghai

Professor He Ben from Shanghai Renji Hospital recently conducted the left atrial appendage closure on two patients with the help of 3D printing technology.

Support by the cardiovascular imaging team, He first collected the CT scan image of the patient, and then used 3D printer to make two left atrial appendage models of the two patients.

Based on the 3D printed models, the professor and his team made a plan and spent 4 hours to conduct the left atrial appendage closure operations.

During the operation, the imaging team provided 4D cardiac color ultrasound to provide convenience.

“3D printing helped us to ascertain the condition and prepare the plan, thus improving the surgery success; at the same time, it helps shorten the learning curve of doctors to master new clinical skills,” the professor said.

Researchers report rare giant blood cyst from bicuspid aortic valveProfessor Zhang Eryong from West China Hospital, Sichuan University and his team recently reported a giant blood cyst originating from the bicuspid aortic valve.

A 22-year-old male patient was admitted to the hospital because of repeated chest pain and syncope. Physical examination was unremarkable except for a systolic murmur on cardiac auscultation. Transesophageal echocardiogram showed a large, very mobile cystic mass (21×17 mm) attaching to the bicuspid aortic valve, which caused severe left ventricular outflow tract obstruction with normal ventricular size and function.

Additional cardiac MRI revealed there was a cyst-like mass attached on the aortic valve (Figure 1C through 1E and

Movie III in the online-only Data Supplement). Finally, a bluish blood-filled cyst (23×17 mm) originating from the bicuspid aortic valve with a broad base was confirmed during surgical operation. Surgical resection of the cyst with concurrent aortic valve replacement was done for this patient. Additional histological examination confirmed that the cystic cavity was surrounded by a fibromyxoid wall with an internal lining of endothelial cells. The patient was discharged uneventfully 7 days after surgery.

Study shows admission useful in predicting short-term outcomes of STEMI patients

Admission Shock Index, an easily calculated index at first contact, may be a useful predictor for short-term outcomes especially for acute phase outcomes in patients with STEMI, according to a study of Professor YangYanmin



CCB

and her colleagues from Beijing Fuwai Hospital published recently.

Included in the study were 7,187 consecutive patients with STEMI. The admission SI was defined as the ratio of admission heart rate and systolic blood pressure. Patients were divided into 2 groups with SI <0.7 and ≥0.7, respectively, based on the receiver operating characteristic curve analysis. The major end points were 7- and 30-day all-cause mortality.

Of 7,187 patients, 5,026 had admission SI <0.7 and 2,161 had admission SI ≥0.7. Those who presented with SI ≥0.7 had greater 7- and 30-day all-cause mortality and major adverse cardiovascular events than patients with SI <0.7. After multivariate adjustment, patients with SI ≥0.7 had a 2.2-fold increased risk of 7-day all-cause mortality (hazard ratio 2.21, 95% confidence interval [CI] 1.71 to 2.86) and 1.9-fold increased risk of 30-day all-cause mortality (hazard ratio 1.94, 95% CI 1.54 to 2.44).

Moreover, admission SI ≥0.7 was also associated with 1.6- and 1.5-fold increased risk of 7- and 30-day major adverse cardiovascular events (hazard ratio 1.63, 95% CI 1.36 to 1.95 and hazard ratio 1.47, 95% CI 1.24 to 1.74, respectively). The C statistic of admission SI for predicting 7- and 30-day all-cause mortality was 0.701 and 0.686, respectively, compared with 0.744 and 0.738 from the Thrombolysis in Myocardial Infarction risk score.

Study shows the association between NC and early stage atherosclerosis

High neck circumference is associated with an increased risk of early stage atherosclerosis in Chinese adults, according to a study by Professor Liang Jun from Xuzhou Central Hospital Affiliated to Southeast University and his team.

The study samples were from a community-based health examination survey in central China. In total 2,318 men and women (18-64 y) were included in the final analyses. Carotid radial pulse wave velocity (crPWV), carotid femoral PWV (cfPWV), carotid artery dorsalis pedis PWV (cdPWV) and NC were measured.

After adjustment for age, sex, lipids, glucose, blood pressure, heart rate, body mass index (BMI), high NC was significantly associated with an increasing trend of cfPWV, cdPWV and

crPWV (P = 0.001, 0.049, and 0.038; respectively).

In addition, the researchers found significant interaction between hypertension status and NC level in relation to cfPWV, adjusted for age, sex, BMI, fasting glucose, lipids and heart rate(P for interaction = 0.034). The associations between NC and cfPWV were significant (P = 0.02) among those with hypertension, but not significant among those without hypertension.

Neck Circumference (cm) was measured with head erect and eyes facing forward, horizontally at the upper margin of the laryngeal prominence with a flexible tape.

Research shows M2.5 concentration was associated with IHD morbidity and mortality

M2.5 concentration was significantly associated with IHD morbidity and mortality in Beijing, according to a research by Professor Zhao Dong from Beijing Anzhen Hospital and his team.

A time-series study conducted in Beijing from 1 January 2010 to 31 December 2012. Data on 369 469 IHD cases and 53 247 IHD deaths were collected by the Beijing Monitoring System for Cardiovascular Diseases, which covers all hospital admissions and deaths from IHD from Beijing’s population of 19.61 million.

The mean daily PM2.5 concentration was 96.2 μg/m3 with a range from 3.9 to 493.9 μg/m3. Only 15.3% of the daily PM2.5 concentrations achieved WHO Air Quality Guidelines target (25 μg/m3) in the study period. The dose–response relationships between PM2.5 and IHD morbidity and mortality were non-linear, with a steeper dose–response function at lower concentrations and a shallower response at higher concentrations. A 10 μg/m3 increase in PM2.5 was associated with a 0.27% (95% CI 0.21 to 0.33%, p<2.00×10−16) increase in IHD morbidity and a 0.25% (95% CI 0.10 to 0.40%, p=1.15×10−3) increase in mortality on the same day.

During the 3 years, there were 7703 cases and 1475 deaths advanced by PM2.5 pollution over expected rates if daily levels had not exceeded the WHO target.

The findings provide a rationale for the urgent need for stringent control of air pollution to reduce PM2.5 concentration.



CCB

REGULATORY REVIEWREGULATORY REVIEWChinese Expert Consensus for Diagnosis and Treatment of Syncope: 2014 Updated Version

The new Chinese expert consensus for diagnosis and treatment of syncope consists of the following parts:

1. Classification and pathophysiology;

(1) Definition

(2) Classification

(3) Pathophysiology

2. Diagnosis and risk stratification;

(1) Preliminary assessment

(2) Diagnosis

(3) Risk stratification

(4) Auxiliary examinations

3. Treatment;

(1) General principle

(2) Reflex syncope

(3) Orthostatic hypotension and orthostatic intolerance syndrome

(4) Cardiac syncope

4. Special problems;

(1) Senile syncope

(2) Syncope in children

(3) Driving and syncope

5. Hospital department recommended for patient admission.

6. Appendix: head-up tilt test (HUTT).

Compared with the 2008 Chinese expert consensus for syncope diagnosis and treatment, modifications were made in the new version as below:

1. Orthostatic intolerance syndrome was added into the class of orthostatic syncope;

2. Arrhythmias syncope and syncope caused by organic heart disease was combined as one class, cardiac syncope;

3. In the subclassification of reflex syncope, hyperirritable carotid sinus syndrome was listed as one independent subclass for the first time;

4. The characteristics of orthostatic syncope was more specifically described;

5. For the diagnostic criteria of arrhythmias syncope, sinus bradycardia was changed from HR<50/min to <40/min, and atrioventricular block from type I second-degree A-V block to type II second-degree A-V block, or third-degree A-V block;

6. Diagnostic criteria for syncope caused by organic heart disease was listed independently;

7. Risk stratification was recommended for those with uncertain diagnosis of syncope;

8. Carotid sinus massage (CSM) and assessment for upright position was listed as the first two auxiliary examination;

9. For treatment of reflex syncope, physical counter-pressure movement (PCM) was mentioned as first-line therapy for the first time;

10. Discussion of heritable ion channel disease was deleted from treatment of arrhythmias syncope;

11. Specific indications for implantable cardioverter-defibrillator (ICD) implantation for patients with high risk for cardiac sudden death (syncope with unclear reason);

12. 24 hour ambulatory blood pressure monitoring was firstly recommended for senile syncope patients suspected with unstable blood pressure;

13. Children syncope was firstly classified into two specific subclass: infant reflex syncope attack and transient loss of consciousness caused by asphyxial hypoxia;

14. Hospital department recommended for patient admission was firstly listed;

15. Details for head-up tilt test (HUTT) were independently listed as the appendix.



CCB

Registration of imported vascular stents in SFDA, 2013 & 2014(Source: China Cardiovascular Business, based on government data)

Name of stent Manufacturer Country Expiration date Use

LifeStent and LifeStent XL Vascular Stent Angiomed GmbH & Co. Medizintechnik KG

Germany 2018.02.23 Peripheral vascular diseases

Xpert Stent System Abbott Laboratories Vascular Enterprises Ltd. Dublin, Beringen Branch

Swiss 2017.03.24 Peripheral vascular diseases

Zilver Flex 35 Vascular Stent Cook Ireland Limited Ireland 2017.09.17 Peripheral vascular diseases

Absolute Pro Vascular Self-Expanding Stent System Abbott Vascular U.S.A. 2017.09.15 Peripheral vascular diseases

Express LD Vascular Premounted Stent System Boston Scientific Corporation U.S.A. 2019.06.30 Peripheral vascular diseases

Peripheral Vascular Stent System CID S.p.A. Italy 2019.08.20 Peripheral vascular diseases

Intra-coronary stents MINVASYS S.A.S. France 2018.05.29 Coronary artery diseases

Endeavor Sprint Zotarolimus-Eluting Coronary Stent System

Medtronic, Inc. U.S.A. 2017.08.26 Coronary artery diseases

Everolimus Eluting Coronary Stent System Abbott Vascular U.S.A. 2018.01.27 Coronary artery diseases

XIENCETM V Everolimus Eluting Coronary Stent System

Abbott Vascular U.S.A. 2017.09.09 Coronary artery diseases

Everolimus Eluting Coronary Stent System Abbott Vascular U.S.A. 2017.09.15 Peripheral vascular diseases

Endeavor Resolute Zotarolimus-Eluting Coronary Stent System

Medtronic Inc. U.S.A. 2017.11.04 Coronary artery diseases

Coronary Stent System B.Braun Melsungen AG Germany 2019.07.09 Peripheral vascular diseases

ParaMount Mini GPS Stent System ev3,Inc. U.S.A. 2017.09.15 Vascular diseases

ProtégéTM GPSTM Self-Expanding Stent System ev3,Inc. U.S.A. 2018.04.08 Peripheral vascular diseases

Endurant Stent Graft System Medtronic Inc. U.S.A. 2018.03.12 Peripheral vascular diseases

Azule CN CoCr Alloy Coronary Stent Delivery System

OrbusNeich Medical, B.V. Netherlands 2017.03.14 Coronary artery diseases

Coronary stent delivery systems Blue Medical Devices BV Netherlands 2017.04.17 Coronary artery diseases

OMEGA Platinum Chromium Coronary Stent System

Boston Scientific Corporation U.S.A. 2017.11.18 Coronary artery diseases

PALMAZ BLUE Stent System Cordis Cashel U.S.A. 2017.09.28 Peripheral vascular diseases

Peripheral Self-Expanding Stent System CID S.p.A. Italy 2019.06.15 Peripheral vascular diseases

Infrapopliteal Artery Stent System CID S.p.A. Italy 2019.07.09 Peripheral vascular diseases

Assurant Cobalt Over-the-Wire Iliac Stent System Medtronic Inc. U.S.A. 2019.07.22 Peripheral vascular diseases

Absolute Pro Peripheral Self-Expanding Stent System

Abbott Vascular Ireland 2019.08.20 Peripheral vascular diseases

GORE EXCLUDER AAA Endoprosthesis W.L. GORE & ASSOCIATES, INC. U.S.A. 2017.08.26 Abdominal aorta diseases

Coronary Stent System Biotronik AG U.S.A. 2017.08.19 Coronary artery diseases

Taxus Liberté Paclitaxel-Eluting Coronary Stent System


PROMUS Element Plus Everolimus-Eluting Coronary Stent System




CCB

MARKET REPORTMARKET REPORTChina cardiovascular mortality on the rise According to China Cardiovascular Disease Report 2013, there are currently about 290 million cardiovascular disease patients in China, compared with 230 million cardiovascular disease suffers two year before, showing a rising trend. About one in every five adults is a cardiovascular disease sufferer.

Of the 290 million cardiovascular disease patients, 270 million suffer from hypertension, 7 million stroke, 2.5 million myocardial infarction, 4.5 million heart failure, 5 million pulmonary heart disease, 2.5 million rheumatic heart disease, 2 million congenital heart disease.

The national disease surveillance system showed that the mortality of cardiovascular disease rose from 240.03/100,000 in 2004 to 268.92/100,000 in 2010. This was mainly due to the rise in ischemic heart disease deaths. The mortality rates of ischemic heart disease, hypertensive heart disease, and cerebrovascular disease rose 5.05%, 2.08% and 1.02% respectively during the six years, while the rheumatic heart disease mortality dropped 7.02% year on year.

Cerebrovascular disease

Cerebrovascular disease prevalence in China is on the rise. The morbidity for city residents is higher than the rural residents. Ischemic stroke accounted for 66.4%, cerebral hemorrhage, accounted for 23.4%.

From 2003 to 2011, the cerebrovascular disease mortality for China’s rural residents was higher than urban residents. In 2011, cerebrovascular disease mortality was 125.37/10 for urban residents, and 136.68/10 for rural residents. Based on China’s Sixth Population Census, it can be estimated that 834,500 urban residents and 921,100 rural residents died of cerebrovascular diseases in 2011.

Coronary heart disease

The 2008 China health service survey shows that the ischemic heart disease prevalence was 7.7 ‰ in China (15.9 ‰ in urban area, and 4.8 ‰ in rural area), which increased significantly from 4.6 ‰ showed by the 2003

survey (urban 12.4 ‰, rural 2.0 ‰).

From 2002 to 2011, coronary heart disease mortality rate was on the rise in China. In 2011 coronary heart disease mortality was 95.97/100,000 in urban areas, 75.72/100,000 in rural areas, higher than that for 2010 (86.34/100,000, 69.24/100,000).

China’s coronary heart disease mortality 2002-2011

39.56 42.1

64.67

86.34

28.68 24.89 22.2

51.89

71.27 75.72

57.146.2746.1

91.4194.96 95.97

69.24

27.5733.74 45.29

0

20

4060

80

100

120

2002 2003 2004 2005 2006 2007 2008 2009 2010 2011

Urban residents Rural Residents

Overall, the mortality rate of acute myocardial infarction was on the rise from 2002 to 2011. Starting in 2005, acute myocardial infarction mortality rate in rural areas grew rapidly, and surpassed that in urban areas in 2009, 2010 and 2011. Adjusted for geographic region and sex, myocardial infarction mortality increases with the age - rising sharply on people over 40.

Arrythmia

A retrospective survey on the patients in the cardiac department of 22 provincial hospitals in China showed that 26.8% of hospitalized patients suffered from arrhythmia. Of arrhythmia, atrial fibrillation ranked first (35.0%), followed by paroxysmal supraventricular tachycardia (28.0%), sick sinus syndrome (11.9%) and ventricular premature beat (11.6%).

According to a survey in 2004, atrial fibrillation prevalence was 0.77% in people aged 35 ~ 59 (male 0.78%, female 0.76%). And 19.0% of male AF patients and 30.9% of female AF patients also suffer from heart valve disease. The history of myocardial infarction, left ventricular hypertrophy, obesity, drinking are the risk factors of AF.

Heart failure

According to a survey of 15,518 people in 10 provinces,



CCB

the prevalence of chronic heart failure in people aged 35 to 74 in China is 0.9% - male 0.7%, female 1.0%. The heart failure prevalence grows significantly with the age. Heart failure prevalence in North China is higher than South China (1.4% vs 0.5%), and that for urban areas is higher than rural areas (1.1% vs 0.8%). Over the past thirty years, the chief cause of heart failure changed to coronary heart disease (CHD) from rheumatic valvular heart disease.

Sudden cardiac death (SCD)

The incidence of SCD is 41.8/100,000 for Chinese people. The incidence is 44.6/100,000 for men and 39.0/100,000 for women, which rises significantly with the age. It is estimated that there are 544,000 new SCD cases in China each year.

Pulmonary arterial hypertension

A survey 31 Grade-Three Class-One hospitals in China showed that PAH related to congenital heart disease 49.6%, idiopathic PAH 27.2%, PAH related to connective tissue diseases 11.6% and chronic thromboembolic PAH, 11.6%.

Cardiac surgery

In recent 10 years, cardiac surgery volume was increasing year by year on the Chinese mainland, amounting to 203,195 in 2012. Of these, 158, 597 cases were extracorporeal circulation operations. In 2012, a total of 84,439 cases of congenital heart disease surgery, 218 cases of heart transplantation (including 5 cases of heart and lung transplantation), and 399 cases of extracorporeal membrane oxygenation treatment were conducted on the Mainland and Hong Kong.

Cardio-cerebrovascular disease inpatient visits

In 2012, there were 14.35 million cardio-cerebrovascular disease inpatient visits in China’s hospitals, accounting for

12.24% of the total inpatient visits in China’s hospitals. Among them, there were 7.525 million cardiovascular disease inpatient visits, and 6.8279 million cerebrovascular disease inpatient visits.

In 2012, the ischemic heart disease inpatient visits numbered 5.05 million (295,200 acute myocardial infarction inpatient visits) and cerebral infarction inpatient visits, 4.12 million, accounting for 35.17% and 28.72% respectively. They were followed by high blood pressure, 2.24 million visits; intracranial hemorrhage, 1.20 million visits; rheumatic heart disease, 238,300 visits. About 2.39 million diabetic patients were discharged from hospital.

Cardiovascular diseases inpatients discharged in China, 1980-2012

(Unit:10,000 person time)

23.8388.71

504.71

223.9413.6216.2415.4342.4715.03 70.644.5718.09

0

100

200

300

400

500

600

1980 1990 2000 2012

Rheumatic heart disease Ischemic heart diseaseHypertension

Cardio-cerebrovascular disease inpatient expenses

In 2012, the total hospitalization expenses of acute myocardial infarction were RMB 4.961 billion in China, intracranial hemorrhage, RMB 14.706 billion, and cerebral infarction, RMB 29.845 billion. The average expense per inpatient was RMB 16802.4 for acute myocardial infarction, RMB 12207.4 for intracranial hemorrhage, and RMB 7241.3 for cerebral infarction, increasing 5.78%, 4.80%, and 0.96% year-on-year since 2004.

POC PROFILEPOC PROFILECardiology Department, Peking University First Hospital

Scale Wards 三个专业病房、一个监护室.

心内科下辖心导管室、心电图室、动态心电图及动态血压检查室、运动心电图室、临床电生理检查

室、超声心动图室、生化检查室等

Beds 98



CCB

Equipment HP多导生理监护仪、900C呼吸机、体外起搏-除颤监护仪、可移动式C形臂X光机、床旁超声心动图

机等整套现代化监护、治疗、抢救设施

Doctors 心内科现有在职职工107人，其中医生27人（正高级职称6人、副高级职称人员8人、中级职称人员13人）、科研人员1人（中级1人）、技术人员11人、护士68人。

Clinical Outpatient 门诊量达到8万人次

Inpatient 年收治住院病人近4000例，其中疑难病占13%，急危重症占28%，抢救成功率达92%，

Surgery 2012年度冠脉介入手术1600例。

Technology 开展技术复杂的器质性心脏病室性和房性心律失常的射频消融、膜部室间隔缺损介入封闭术、心房

颤动三维CARTO电解剖标测下行射频消融术，三腔起搏器对心衰病人行双心室同步化治疗，以及心

脏转复除颤器治疗恶性室性心律失常等，居国内先进水平，并取得了很好的临床疗效，心内科在急

性心肌梗死绿色通道、急性心肌梗死再灌注治疗、血流动力学监测、冠心病介入治疗、心律失常介

入治疗、永久起搏器植入、小儿心律失常介入治疗、先心病介入治疗等领域内继续保持国内领先水

平。每年完成成人及儿童射频200例左右，成功率高，治疗合并症少，其中儿科射频例数，为国内之

首，迄今心房颤动的射频消融治疗数已逾百例，位居全国首列。心脏起搏治疗技术先进，安装起搏

器的患者年龄最小者仅6个月，是全国年龄最小的接受永久起搏治疗的患者。是国内最早开展埋藏式

心脏复律除颤器(ICD)治疗恶性室性心律失常的单位之一，这方面的工作已达到世界先进水平。

北大医院心内科不仅是国内最早开展经皮冠状动脉腔内成形术(PTCA)的单位，而且在国内率先开展

了冠状动脉旋切术(1991年)、冠状动脉支架术(1992年)、冠状动脉旋磨术(1993年)、冠状动脉内超声

及血流多普勒检查(1994年)等多种冠心病介入诊疗新技术,管理严格,操作规范,病例的复杂程度和治

疗效果得到了国内外同行的认可，经常接诊从全国各地转诊来的复杂病例。专家个人完成病例数在

国内名列前茅，先后帮助数百家医院开展冠心病介入治疗工作。培训的介入医师遍布全国。

Research 心内科2000年定为211工程重点学科，2002年成为国家重点学科。本科室同时是北京大学心血管病临

床研究所，承担了多项国家和省部级科研任务，取得了多项科研成果和科技进步奖。心血管内科是

该院最早的临床药理基地之一，已完成多项新药临床试验。心内科设有实验室，包括生化室、分子

生物学室、细胞室，细胞电生理室。

主要研究方向：

1、冠心病介入治疗新技术及介入术后再狭窄机制的研究。

2、冠心病一级及二级防治研究：承担 “八六三”计划(分子搭桥术与血管成形术――VEGF基因治

疗梗塞性血管病)的工作。在动脉粥样硬化发病机制研究领域，已先后开展过Hcy,雌激素，血脂、红

细胞L-精氨酸/一氧化氮途径等对粥样硬化发展的影响与干预研究。

3、心肌及血管内皮损伤机制及防治研究：先后进行过心肌缺血及再灌注损伤、血管内皮功能损

伤机制的研究，对炎症因子、血管紧张素系统、血管活性物质如ET、ox-LDL在此方面的损伤作

用，NO，肾上腺髓质素等物质的保护性作用及机理均有深入研究。缺血预处理的细胞保护作用及其

分子机制的研究、肾上腺髓质素在心血管疾病中的病生理意义、血管内皮损伤机制及其保护的实验

研究等先后获得各部委科技成果奖，在国内处于本领域研究的前沿地位。

4、基因多态性研究：近5-6年来，与美国哈佛大学公卫学院流行病学教研室密切合作，开展了一系列

冠心病发病与诊治的相关基因多态性研究，如“心肌梗塞与其侯选基因的相关研究”，“苯那普利

的降压效应与ACE基因和AGT基因多态性的关系”、“肾上腺素β3受体基因W64R多态性与动脉粥样

硬化危险因素及苯那普利疗效之间的关系”以及“冠脉支架植入术后再狭窄与炎症相关候选基因的

关系”等研究课题。

5、冠心病诊断技术的应用与评估：充分发挥冠心病临床诊治水平高，冠脉造影检查病人人数多，北

大医院为多学科发展的大型综合医院的优势，先后开展了动态心电图、运动试验、超声负荷试验、

同位素心肌灌注显像在冠心病诊断中价值和应用的研究，近年来，与医学影像科密切合作，开展

CTA、核磁共振等检查在冠心病诊断、预后判断等方面的研究，已取得初步成果。

6、心脏电生理：是中国最早开展心脏电生理诊断治疗技术和研究的单位，在心律失常的电生理检查

和射频消融治疗、起搏器治疗、ICD以及小儿心律失常的射频消融治疗的临床研究中已取得突出成

绩，在国内处于领先地位。近年来在房颤的药物和射频消融治疗、心力衰竭的双心室起搏心脏同步

化治疗方面的研究也取得很大进展。

几年来，本学科共获国家自然科学基金、教育部、科技部、卫生部、财政部、北京市、北京大学等

资助1770万元。完成28项国家级或部级科研项目。在国外杂志发表论文20多篇，在国内核心期刊发

表论文百余篇。其中血管内皮损伤机制及其保护的实验研究获2003年教育部科学技术进步一等奖。

Training base 卫计委冠脉介入医师培训基地、卫计委心律失常介入诊疗培训基地

卫生部批准的全国冠心病介入治疗质量控制中心,同时也是中华医学会心血管疾病介入治疗培训中

心、蛇牌学院心血管介入治疗培训中心、北京大学-杜克大学心血管培训中心、ACC合作培训基地。

科主任霍勇教授是国际知名专家，是中华医学会心血管病分会候任主任委员、中国医师协会心血管

内科医师分会会长、卫生部心血管介入诊疗培训专家组组长。

Peer/patient evaluation 复旦版 2013 年度最佳专科医院排行榜榜单全国心内科排名第5名。



CCB

Cardiology Department, Peking University People’s Hospital

As a national leader in prevention, diagnosis and treatment of cardiovascular diseases, the cardiology department has lots of “firsts” in China: first Chest Pain Center, first radiofrequency ablation case and first loop recorder placement. Moreover, cardiologists in the department handle

the most cases of cardiovascular implantable electronic device infections in Asia. During the past several years, the department was grant recipients of 21 national projects and three international joint programs. It is now an American Heart Association (AHA) Professional Resource Center.

Scale Wards 3个病区。冠心病监护病房(CCU)及10个辅助科室，即心脏电生理室、超声心动室、心电图室、平板

运动试验室、动态心电图室、直立倾斜试验室、动态血压监测室、心肺运动试验室、血液流变学实

验室及血管功能检查室

Beds 144Equipment 心导管室设有大功率全数字化心血管造影机,冠脉内超声诊断仪,激光发生器,主动脉气囊反搏治疗机

及其他配套设施,备有各种类型和规格的导管,球囊,支架,封堵伞等器材。

Doctors 2014年,心内科现有员工138人，其中医生52人，护士72人，技术人员14人，具有高级职称人员36人，具博士及硕士学位人员占30.4%。

Scale Wards 2012年门诊量达到10.3万人次

Beds 2012年住院病人数6000人次

Equipment 2012年度冠脉介入手术1500例Technology 主要从事冠脉造影，经皮冠状动脉腔内成形术，冠状动脉斑块旋切术，冠状动脉斑块旋磨术，经皮

气囊瓣膜扩张术，动脉导管未闭封堵术，房间隔和室间隔缺损封堵术，肺动脉造影和肺动脉栓塞碎

栓术，心内膜活检以及血液动力学监测，有创性左室功能评价，心包穿刺，主动脉内气囊反搏等医

疗活动。

Research 近5年来共获得包括“十二五”国家科技支撑项目、国家高技术研究发展计划(863计划)、国家自

然科学基金、北京市科技计划重大项目在内的国家级和省部级课题50项；近5年发表论文共369篇。2011年，成功建立动脉粥样硬化疾病生物数据库(Biobank)，目前已保存逾千例生物样本，

为开展大规模临床研究奠定了基础。此外，牵头或参与了多项国际多中心临床试验项目，包括

VALUE、RELY、Cypher select、EPICOR-Asia、ROKECT、ACE、TIMI54等。相关科研成果获得3项国家科技进步二等奖、1项教育部高等学校科学研究优秀成果科技进步二等奖、3项中华医学科技奖

三等奖、1项中华预防医学会科学技术奖三等奖、1项北京市科学技术奖二等奖、2项北京市科学技术

奖三等奖和2项华夏医学科技奖三等奖。

Training base 全国和北京市住院医师规范化培训基地、全国和北京市专科医师培训基地、卫计委冠脉介入医师培

训基地、北美心脏起搏与电生理学会(NASPE)心电生理起搏培训基地及卫计委心律失常介入诊疗培

训基地。

Peer/patient evaluation 复旦版2013年度最佳专科医院排行榜榜单全国心内科排名第6名。

Cardiology Department, West China Hospital

Scale Wards 2个病区。1CCU 1个分院

Beds 215床7间心内科专用心导管室、超声心动图室、心电图室、运动平板试验室及动态心电图室。

Equipment 超声心动图仪7台，1台便携式床旁超声心动图机

Doctors 现有工作人员169人(医生50人，护士105人，医技部门技师14人)，其中正高级职称21人，副高级职

称13人，博士生导师6人，硕士生导师10人。95%以上的医生拥有博士或硕士学位，90%以上的护士

具有大学本科或大专学历。80%以上的医生先后赴美国、加拿大、德国、澳大利亚、新加坡、香港等

国家和地区进修学习。目前，每年有10-20名医生出国参加国际心脏病学术会议及短期培训，

Scale Wards 2013年门诊量达到11.3万人次

Beds 近三年来，每年住院治疗的病人超过8000多例。

Equipment 介入治疗例数居西部地区首位。其中射频消融例数占全省42%，房颤及病理性室速消融占90%，CRT占54.5%，ICD占61.7%，起搏器置入占22%，冠脉介入治疗占25.6%，先心病介入治疗占31%。

Technology 包括了冠状动脉造影及经皮冠状动脉球囊扩张术、二尖瓣球囊成形术、快速心律失常的射频消融

术、先天性心脏病介入治疗、冠状动脉支架植入术、肥厚型心肌病室间隔化学消融术、双心室起搏

(CRT)治疗心力衰竭，三维电解剖标测指示下导管消融治疗心房颤动、病理性室速等。在国内率先开

展双心室起搏治疗心衰，射频消融治疗快速心律失常，作为国内最早开展经导管主动脉瓣置换术的

几家医院之一，目前病例数居于全国首位。



CCB

KOL PROFILEKOL PROFILEHuo Yong (霍勇) – Peking University First Hospital

Research 2007年，通过了教育部本科教学评估，获得好评。近三年来，共获国家“十一五”支撑计划、国

家“863”高技术研究发展计划、国家自然科学基金面上项目等国家级科研项目15项。获得国际合作

项目23项，省、部、厅级科研项目23项。近三来，以该科为通讯作者单位发表的SCI全文有55篇，最

高影响因子31.718，累积影响因子202.724。获国家级科技进步奖1项，省级科技进步奖4项，市级科

技进步奖3项。

Training base 卫生部评为介入诊疗技术培训基地(冠心病介入、心律失常介入、先心病介入).国家心血管临床新药

试验(GCP)基地

Peer/patient evaluation 复旦版 2013 年度最佳专科医院排行榜榜单全国心内科排名第12名。

Personal profile 北京大学第一医院心内科主任、心血管病研究所所长、心脏中心主任

Specialty 1991年开始从事冠心病介入诊疗工作19年，平均每年完成病例数700余例。

Research project 自90年代起，开始引进冠心病介入新技术，主持多项我国自主知识产权介入器械的研发工作，推动先进

技术理念在国内的推广普及；在卫生部的领导下，建立完善我国心血管介入的质量控制和规范化体系，

为我国冠心病介入诊疗事业做出了巨大贡献；同时，站在更高的层面为我国心血管专业及专科医师的发

展筹谋布局，并致力于积极推动我国心脑血管疾病等慢病防控事业的进步与发展。

Concurrent post 北京大学第一医院学术委员会委员、主任医师、教授、博士生导师，中华医学会心血管病分会候任主任

委员，中国医师协会心血管内科医师分会会长，中华医学会内科学分会常委兼秘书，卫生部心血管疾病

介入培训专家组组长，全国冠心病介入治疗质量控制中心主任，中国民主促进会中央委员，北京市西城

区政协委员。

Academic achievement 担任中华医学会心血管介入治疗培训中心主任后，先后帮助全国各地400余家医院开展冠心病介入治疗，

并在29个省、市、自治区举办了培训班和研讨会，极大提升了我国冠心病介入治疗的整体水平。2002年起，出任卫生部心血管介入诊疗技术管理专家组组长等职务，在卫生部领导下，先后协助出台了卫生部

技术管理规范，推动成立一百多个卫生部培训基地和质控中心，建立起心血管介入治疗的认证、培训、

质控制度；主持建立冠心病介入治疗网络直报系统，对我国心血管介入治疗的基本资料进行了实时、全

面、系统的收集，使我国在国际上率先实现从国家层面对介入病例的数量和质量实现实时监控。为心血

管介入治疗摆脱粗放型发展，走向规范化做出重大贡献。

万方医学网数据库显示至2014年12月，共发表306篇论文。

Patient evaluation 好大夫网站的患者投票数据显示，至2014年12月，获得18票的支持，对疗效和态度的满意度均为100%。

Hong Tao (洪涛) – Peking University First HospitalPersonal profile 北京大学第一医院心内科副主任、心血管病研究所副所长、教授、主任医师、博士研究生导师，曾在新

加坡中央医院国立心脏中心进修冠心病介入技术。

Specialty 1993年开始从事冠心病介入诊疗工作，平均每年完成病例数500余例。

Research project 参与国家”八五”攻关、”九五”攻关、卫生部及北京市自然科学基金课题研究工作，主持完成国家自

然科学基金课题研究一项，任国家科技部“十一五”科技支撑计划子课题负责人一项。

Concurrent post 中国医师协会心血管内科医师分会委员、中国生物医学工程学会介入医学工程分会常委、中华中医药学

会介入心脏病学专家委员会常委，卫生部心血管内科专科医师准入工作专家组秘书，国家医师资格考试

临床类别试题开发专家委员会委员、北京大学医学部临床医学专业教学委员会内科教学组成员及住院医

师规范化培训内科学考核组专家、北京市劳动能力鉴定委员会医疗卫生专家库成员、北京市西城区劳动

能力鉴定委员会医疗鉴定专家、北京市西城区医学会医疗事故鉴定专家库专家。

Academic achievement 万方医学网数据库显示至2014年12月，共发表70篇论文。


Li Jianping (李建平) – Peking University First HospitalPersonal profile 现任北京大学第一医院心内科副主任、心血管病研究所副所长、主任医师、教授、硕士研究生导师，

Specialty 1997年开始从事冠心病介入诊疗工作，近几年平均每年完成病例数200余例。



CCB

Concurrent post 中华医学会心血管病分会青年委员会副主任委员。



Chen Ming (陈明) – Peking University First Hospital

Personal profile 男，医学博士。曾在澳大利亚进修冠心病介入诊疗技术　现任北京大学第一医院心内科主任医师、副教

授、硕士研究生导师。

Specialty 1997年开始从事冠心病介入诊疗工作，已完成冠心病介入治疗超过5000例。

Research project 2011年与霍勇教授共同主编《心血管病实验动物学》。2011年主持国家863课题子项目-双药支架动物实

验研究。

Concurrent post 2009年被卫生部医政司聘为冠心病介入治疗培训导师。2010年受聘为《中国医学前沿杂志》编委。

Academic achievement 2011年与霍勇教授共同主编《心血管病实验动物学》。万方医学网数据库显示至2014年12月，共发表64篇论文。

Patient evaluation 好大夫网站的患者投票数据显示，至2014年12月，获得8票的支持，对疗效的满意度为100%。

Ding Yansheng (丁燕生) – Peking University First Hospital

Personal profile 北京大学第一医院心内科电生理室及心功能室主任

Specialty 1991年开始最早在国内开始开展射频消融术并大力推动该技术的发展，每年指导并帮助外院完成射频消

融术4百台以上，每年植入起搏器数百台，包括三腔起搏和自动转复除颤器。同时还开展先天性心脏病介

入治疗及风湿性心脏病二尖瓣球囊扩张的介入治疗等。

Concurrent post 兼任中国医药生物技术协会心电学技术分会常委、中华医学会电生理与起搏分会委员、中国生物工程学

会心电生理与起搏分会常委、中国介入心脏病学杂志编委、中华心律失常学杂志编委、中国心电学杂志

编委﹑中华医学会电生理学会房颤工作组委员。



Hu Dayi (胡大一) – Peking University People’s HospitalPersonal profile 主任医师、教授、博士生导师.现任北京大学人民医院心研所所长、心内科主任。1985-1987在美国纽约

州立大学医学院和芝加哥伊利诺大学医学院进修心脏电生理和介入心脏病学

Specialty 冠心病和心律失常的药物及介入治疗、高血压、心律失常诊断与射频消融。

被誉为我国心律失常射频消融的创始人。

在我国率先成功开展射频消融根治快速心律失常技术，获1993年卫生部科技进步二等奖，1995年国家科

技进步二等奖，已向全国150多家医院推广普及此项技术。积极推动我国冠心病的外科和介入治疗。

Research project 承担多项国家、省部级、国际合作科研课题。在冠心病介入治疗和我国心血管疾病预防医学的发展方面

作出了贡献。多次组织牵头或参与国际大规模、多中心临床实验，填补了我国在这一领域的空白。

Concurrent post 中华医学会心血管病分会主任委员中国生物医学工程学会心脏起搏与电生理分会主任委员《中国医药导

刊》主编



Wang Weiming (王伟民) –Peking University People’s Hospital

Personal profile 冠脉介入培训基地负责人

1998年至1999年间在德国埃森大学医院学习冠心病介入治疗

Specialty 冠心病、瓣膜性心脏病、高血压病、心力衰竭、介入性心脏病

Research project 已完成多项多中心的药物及介入治疗相关课题。承担国家医学科技攻关课题及国家211工程科研项目，并

获北京市科学技术进步奖叁等奖。

进行“十一五”国家科技支撑计划、863计划、北京市科委科技攻关项目等课题。

Concurrent post 中华医学会心血管病分会冠脉介入组成员，中华医学会心血管病学分会中国胸痛中心认证工作委员会副

主任委员，北京医师协会心血管内科专科医师分会副会长，北京医师协会内科分会常务理事，亚太地区

介入心脏病学学会委员，卫计委心血管疾病医疗质量控制中心冠脉介入专家组成员，美国心脏介入协会

(FSCAI)委员。



CCB


Patient evaluation 好大夫网站的患者投票数据显示，至2014年12月，获得36票的支持，对疗效和态度的满意度为97%和94%。

Guo Jihong (郭继鸿) – Peking University People’s Hospital

Personal profile 男，主任医师，教授，心内科副主任、心脏电生理室主任

Specialty 在国际上首先提出旁道裂隙现象、在国内首先记录窦房结电图、与他人合作研制心脏程序刺激检查治疗

仪等科研成果，荣获国家教育委员会和国务院学位委员会授予的“有突出贡献的博士学位获得者”称

号。与人合作开发研制的具有中国特色的心脏程序刺激检查治疗仪目前仍广泛应用于临床。1987年调入

北京大学人民医院从事医疗、教学及科研?作。

1988年，作为访问学者在美国斯坦福大学医学院从事心电生理学研究。于1989年拒绝国外多方挽留毅然

回国，并创建北京大学人民医院临床心电生理室，1991年率先完成了国内第一例射频消融术。

他最先将双房同步起搏、动态心房起搏以及多程序起搏预防治疗房颤、双室同步起搏及右室双部位起搏

治疗充血性心衰、双腔起搏治疗肥厚梗阻性心肌病、防治血管迷走性晕厥等新观点、新概念和新技术引

入国内，而且丰富和发展了节律重整、折返性早搏、拖带现象等许多心电学理论，并充分应用于临床实

践中。

Research project 他承担了多项卫生部部级科研项目，获得多项科技成果奖。

Concurrent post 中华医学会心电生理和起搏学分会常委、秘书长，博士生导师、中国心功能学会常委，中华心律失常学

杂志副主编，中华医学杂志编委，中国实用内科杂志常委，临床心电学杂志副主编，心血管诊疗技术杂

志主编等职务。


Patient evaluation 好大夫网站的患者投票数据显示，至2014年12月，获得19票的支持，对疗效和态度的满意度为95%和90%.

Li Xuebin (李学斌) – Peking University People’s HospitalPersonal profile 男，主任医师，副教授，硕士生导师

Specialty 心律失常,射频消融,心脏起博器，先天性心脏病介入治疗.

截止目前共完成各种类型室上性心动过速、不良性窦速、心房扑动、房性心动过速、室性心动过速、阵

发性心房颤动等射频消融根治术上万例，其中仅儿童病例多达数百例，植入永久心脏起搏器及ICD达数千

例，风心病及先心病介入治疗数百例.

是目前国内完成双室起搏治疗心力衰竭最多病例的术者之一。

Research project 作为主要术者之一在国内首先完成了国内第一例植入性心电检测器，其“起搏器新技术的开发与应用”

获北京市科学技术二等奖。“心电图新概念、新技术的临床研究与应用”获中华医学科技奖三等奖。

Concurrent post 中华医学会心电生理和起搏学会委员，中国心律学会常委，中国心电学会常委，中国循证心血管医学杂

志副主编，中国心脏起搏电生理杂志，临床心电学杂志编委等职务


Patient evaluation 好大夫网站的患者投票数据显示，至2014年12月，获得42票的支持，对疗效和态度的满意度均为100%.

Huang Dejia (黄德嘉) – West China HospitalPersonal profile 男，副主任医师，教授，副院长，博士生导师，1981年于华西医科大学获医学硕士学位，留校后于附属

第一医院历任住院医师、Doctor-in-charge。Specialty 心律失常诊治，冠心病介入治疗近10年来，所领导的小组共对5000余例心脏病人采用介入新技术治疗，

成功率在95%以上。

Research project 1993年12月在国内首次成功地采用射频消融术治疗先天性三尖瓣下移畸形含并右侧房室旁路(1994年1月12日健康报报道)。1999年5月在国内首次开展双心室起搏术治疗顽固性心衰获成功。多次应邀到上海、

昆明、重庆、济南、天津、乌鲁木齐、兰州等城市的大医院帮助开展新技术。

Concurrent post 担任本专业国内三大学会(中华医学会心血管病学会、心肌电生理与起搏学会，中国生物医学工程学会心

脏起搏学会)常委及四川省心血管病专委会主任委员职务。

中华医学会心血管病分会副主任委员，四川心血管病专委会主任委员，中华医学会心电生理与起博分会

侯任主委，中华心血管病杂志、中华心律失常杂志、中国介入心脏病学杂志编委。多次在全国性学术会

议上主持会议或作专题学术报告。

Academic achievement 多次应邀参加国际学术会议，专著3部，获省部级科技进步将多项，国家自然科学基金等资助项目多项。

培养硕士研究生及博士生数十人。

万方医学网数据库显示至2014年12月，共发表188篇论文。




CCB

Jiang Jian (姜建) – West China Hospital

Personal profile 男，主任医师，教授，硕士生导师。1990年在德国进修临床心内电生理学

Specialty 心内电生理检查及射频消融治疗快速心律失常

Research project 华西医院心脏内科快速心律失常亚专业的学术带头人

Concurrent post 中华医学会起搏与电生理分会委员



Zeng Zhi (曾智) – West China Hospital

Personal profile 男，主任医师，教授，副院长，博士生导师

Specialty 疑难心脏疾病的诊治、风心病和先心病的介入治疗。

已完成二尖瓣球囊成型术2000多例；在西南地区首先开展先心病的介入治疗，已完成先心病介入治疗

1000多例，安置起搏器数百余例，

Research project 课题负责人，承担了国家科技部“十五”和“十一五”攻关项目各一项，心血管支架和药物涂层的研制

和开发(863子课题)一项、教育部博士点基金项目两项和四川省科技厅应用基础研究项目四项。先后在国

内外核心期刊发表文章100余篇，作为副主编及参编5部国家级专著。获国家科技进步二等奖一项，获四

川省省科技进步二等奖、三等奖各一项

Concurrent post 四川省人大常委会委员；中华医学会内科分会常委；中国医师协会血管内科医师分会委员；中华医学会

四川省内科专委会主任委员；中华医学科技评审委员会委员；中国医师协会心血管医师分会常委；中华

医学会内科学分会副主任委员；中华医学会四川省心血管分委会副主任委员；成都市医学会心血管专委

会主任委员；中华人民共和国卫生部医疗服务标准专业委员会委员；中华人民共和国卫生部科技项目评

审专家；中华医学会心血管病学分会委员；中国医师协会心血管分会结构性心脏病委员会副主委；中华

人民共和国教育部科技奖评审专家；中华人民共和国科技部攻关项目评审专家；中华医学奖评审专家；

中国爱心工程国际“先心”培训中心组织委员会主席；四川省心脏起搏与电生理委员会副主任委员；四

川省突发公共卫生事件专家咨询委员会副主任委员；成都医学会心血管专委会主任委员；四川省科技项

目评审专家；《中国医学综合杂志》理事；《四川医学》、《西部医学》、《心血管疾病进展》和《临

床荟粹》等多家杂志编委。



MARKET DATAMARKET DATARanking of cardiologists in Shanghai*

(Source: China Cardiovascular Business)

Rank Name Sex Title Hospital Hospital

grade

Time approved

for conducting

PCI

Years of interventional

practice

Average PCI volume**

1 Ge Junbo葛均波

Male Chief physician Zhongshan Hospial Affiliated to Fudan University

Grade Three Class A

2008.3 20 Between 300 and 500

2 Fan Bing樊冰 Male Chief physician Zhongshan Hospial Affiliated to Fudan University

Grade Three Class A

2008.3 12

3 Wang Weiyi方唯一

Male Chief physician Shanghai Chest Hospial Grade Three Class A

2008.3 20

4 He Ben何奔

Male Chief physician Shanghai Renji Hospial Grade Three Class A

2008.3 17

5 Xu Yawei徐亚伟

Male Chief physician Shanghai No. 10 Hospial Grade Three Class A

2008.3 19



CCB

6 Shen Chengxing沈成兴

Male Chief physician Shanghai Xinhua Hospial Grade Three Class A

2008.3 18 Between 200 and 300

7 Qian Juying钱菊英

Female Chief physician Zhongshan Hospial Affiliated to Fudan University

Grade Three Class A

2008.3 15

8 Wei Meng魏盟


2009.11 17

9 Qu Xinkai曲新凯

Male Associate chief physician

Shanghai Chest Hospial Grade Three Class A

2008.3 13

10 Guo Xingui郭新贵

Male Chief physician Huadong Hospial Affiliated to Fudan University

Grade Three Class A

2008.3 15

11 Li Xinming李新明

Male Chief physician Shanghai East Hospial Grade Three Class A

2008.3 20

12 Qiu Xingbiao仇兴标

Male Chief physician Shanghai Chest Hospial Grade Three Class A

2008.3 13 Between 150 and 200

13 Yan Yan颜彦

Male Chief physician Zhongshan Hospial Affiliated to Fudan University

Grade Three Class A

2008.3 15

14 Hu Jian胡健

Male Chief physician Shanghai Ruijin Hospial Grade Three Class A

2008.3 14

15 Zhang Feng张峰


Zhongshan Hospial Affiliated to Fudan University

Grade Three Class A

2008.3 11

16 Ma Jianying马剑英



Grade Three Class A

2008.3 11

17 Lv Ankang吕安康

Male Chief physician Shanghai Ruijin Hospial Grade Three Class A

2008.3 15

18 Zhang Yachen张亚臣

Male Chief physician Shanghai Xinhua Hospial Grade Three Class A

2008.3 17

19 Wen Qinzhu温沁竹


2008.3 14

20 Lu Zhigang陆志刚


Shanghai No. 6 Hospial Grade Three Class A

2008.3 10

21 Meng Qingzhi孟庆智

Male Chief physician Shanghai Yodak Cardiothoracic Hospial

Grade Three Class C

2008.3 15

22 Ruan Changwu阮长武

Male Chief physician Shanghai No. 8 Hospial Grade Two Class A

2008.3 12

23 Jiang Li蒋利

Male Chief physician Shanghai Changning District Central Hospial

Grade Two Class A

2008.3 16

24 Zhang Dadong张大东

Male Chief physician Shanghai Minhang District Central Hospial

Grade Two Class A

2009.11 20

25 Tao Rong陶蓉

Female Associate chief physician

Shanghai Ruijin Hospial Grade Three Class A

2008.3 12 Between 100 and 150

26 Feng Xiangfei冯向飞


Shanghai Xinhua Hospial Grade Three Class A

2008.3 13

27 Wang Binyao王彬尧


2008.3 16

28 Xu Hao徐浩



2008.3 11

29 Chen Hui陈晖



2008.3 14

30 Zhang Ruiyan张瑞岩



2008.3 11

31 Shen Jieyan沈节艳


2008.3 15

32 Wang Yi王毅



2008.3 10

33 Ma Shixin马士新



2008.3 11



CCB

34 Zhou Guowei周国伟



2008.3 9

35 Yan Wei严卫



Grade Three Class A

2008.3 13

36 Wang Qibin王齐兵



Grade Three Class A

2008.3 14

37 Yang Zhenkun杨震坤



2008.3 10

38 Meng Shu孟舒



2008.3 14

39 Xu Weiping徐伟平



2008.3 13

40 Zhang Qing张清


Shanghai Renji Hospial Grade Three Class A

2008.3 12

41 Zhang Guobin张国兵


2008.3 12

42 Li Weiming李伟明


2008.3 14

43 YeYing叶颖



2008.3 12

44 Zhu Yi朱毅

Male Chief physician Huadong Hospial Affiliated to Fudan University

Grade Three Class A

2008.3 14

45 XuWenjun徐文俊

Male Chief physician Shanghai Tongji Hospial Grade Three Class A

2008.3 16

46 Liang Yulu梁雨露

Male Chief physician Shanghai East Hospial Grade Three Class A

2008.3 19

47 Zheng Hongchao郑宏超

Male Chief physician Shanghai Xuhui District Central Hospial

Grade Two Class A

2008.3 14

48 Qiao Zengyong乔增勇

Male Chief physician Shanghai Fengxian District Central Hospial

Grade Two Class A

2009.11 15

49 Chen Weijie陈维杰



2008.3 12

50 Ge Lei葛雷



Grade Three Class A

2008.3 12

51 Yu Jidan俞济舟



Grade Three Class A

2008.3 13

52 Song Wei宋玮



2008.3 11

53 Du Yongping杜勇平



2008.3 13

54 Bu Jun卜军



2008.3 11

55 Li Jinhua厉锦华



2008.3 15

56 Zhang Jianjun张建军


2008.3 14

57 Li Weizhen李为真



2008.3 9

58 Zhao Junli赵军礼



2008.3 10

59 Chen Wei陈维

Male Chief physician Shanghai Yodak Cardiothoracic Hospial

Grade Three Class C

2008.3 14

60 Song He宋贺

Female Chief physician Shanghai Yodak Cardiothoracic Hospial

Grade Three Class C

2008.3 13

61 Qiu Chaohui邱朝晖


Huadong Hospial Affiliated to Fudan University

Grade Three Class A

2008.3 11



CCB

62 Jiang Jinfa蒋金法

Male Chief physician Shanghai Tongji Hospial Grade Three Class A

2008.3 18

63 Yu Hong于泓


Shanghai Tongji Hospial Grade Three Class A

2008.3 13

64 Liu Xuebo刘学波


Shanghai East Hospial Grade Three Class A

2008.3 14

65 Wang Changqian王长谦

Male Chief physician Shanghai No.9 Hospial Grade Three Class A

2008.3 15

66 Yan Yuqin严毓勤


2008.3 16

67 Xu Peng许澎

Male Chief physician Shanghai No.5 Hospial Grade Three Class B

2008.3 15

68 Zheng Changzhu郑昌柱

Male Chief physician Shanghai No.7 Hospial Grade Two Class A

2008.3 15

69 Gong Hui龚辉


Jinshan Hospial Affiliated to Fudan University

Grade Three Class B

2009.11 12

70 Jin Huigen金惠根

Male Chief physician Shanghai Putuo District Central Hospial

Grade Two Class A

2008.3 14

71 Hu Chunyan胡春燕

Female Chief physician Shanghai Pudong District Nanhui Central Hospial

Grade Two Class A

2009.11 12

72 Wei Yidong魏毅东



2008.3 10 Between 75 and 100

73 Lu Hao陆浩

Male Doctor-in-charge


Grade Three Class A

2009.11 7

74 Zhang Yanzhou张彦周


2008.3 14

75 Shen Linghong沈玲红



2008.3 8

76 Zhao Gang赵钢



2009.11 6

77 Chen Yanqing陈艳清



2008.3 14

78 Jiao Chang’an焦昌安



Grade Three Class A

2009.11 10

79 Song Haoming宋浩明



2008.3 10

80 Ren Yirong任义荣


2008.3 18

81 Qiu Jianping邱建平

Female Chief physician Shanghai Pudong District Gongli Hospial

Grade Two Class A

2008.3 14

82 Wang Jun王骏

Male Chief physician Shanghai Jing’an District Central Hospial

Grade Two Class A

2009.11 9

83 Huang Zuo黄佐

Male Chief physician Shanghai Zhabei District Central Hospial

Grade Two Class A

2009.11 14

84 Zhang Daifu张代富

Male Chief physician Shanghai Pudong District People’s Hospial

Grade Two Class A

2009.11 12

85 Wang Zilong汪自龙


Qingpu Branch, Zhongshan Hospial Affiliated to Fudan University

Grade Two Class A

2009.11 10

86 Zhang Ji张戟



2008.3 11

87 Lu Jide陆纪德


Shanghai Pudong District Gongli Hospial

Grade Two Class A

2009.11 12

88 Quan Weiwei权薇薇



2009.11 9

89 Jin Shuxuan金叔宣



2009.11 9



CCB

90 Zhao Qing赵清



2008.3 9

91 Hou Xumin侯旭敏



2008.3 11

92 Xu Dongjin徐东进


Shanghai Yodak Cardiothoracic Hospial

Grade Three Class C

2009.11 8

93 Xu Jiahong许嘉鸿



2008.3 12

94 Zhuang Shaowei庄少伟



2008.3 17

95 Wang Xiaolong王肖龙

Male Chief physician Shanghai Shuguang Hospial Grade Three Class A

2008.3 14

96 Deng Bing邓兵


Shanghai Longhua Hospial Grade Three Class A

2008.3 12

97 Xie Yushui解玉水


2008.3 15

98 Yang Minquan杨敏全

Male Chief physician Shanghai No. 3 Hospial Grade Three Class B

2009.11 14

99 Chen Rui陈锐


Shanghai No. 8 Hospial Grade Two Class A

2008.3 10

100 Wei Jianming魏建明


Jinshan Hospial Affiliated to Fudan University

Grade Three Class B

2009.11 14

101 Zhu Fu朱福

Male Chief physician Shanghai Xuhui District Central Hospial

Grade Two Class A

2008.3 13

102 Shen Zening沈泽宁

Male Chief physician Shanghai Changning District Central Hospial

Grade Two Class A

2009.11 13

103 Yang Wei杨伟


Shanghai Putuo District Central Hospial

Grade Two Class A

2009.11 10

104 Zhang Shufu张书富

Male Chief physician Shanghai Yangpu District Central Hospial

Grade Three Class B

2009.11 13

105 Zhou Mingcheng周明成

Male Chief physician Shanghai Yangpu District Shidong Hospial

Grade Two Class A

2009.11 14

106 Luo Haiming罗海明

Male Chief physician Yueyang Hospital of Integrative Chinese & Western Medicine Affiliated toShanghai University of TCM

Grade Three Class A

2009.11 15

107 Cai Zhenrong蔡振荣


Shanghai Pudong District Nanhui Central Hospial

Grade Two Class A

2009.11 9

108 Huang Damin黄达民


Chongming Branch, Shanghai Xinhua Hospial

Grade Two Class A

2009.11 10

109 Yang Haiyan杨海燕



2008.3 13

110 Zhu Ning诸宁

Male Chief physician Shanghai Longhua Hospial Grade Three Class A

2008.3 14

111 Zhang Junfeng张俊峰


Shanghai No. 3 Hospial Grade Three Class B

2009.11 12

112 Tang Lan唐岚


Shanghai No.7 Hospial Grade Two Class A

2008.3 12

113 Wang Zhihua王志华

Male Chief physician Shanghai Zhabei District Central Hospial

Grade Two Class A

2009.11 15

114 Zheng Pengxiang郑鹏翔


Shanghai Yangpu District Central Hospial

Grade Three Class B

2009.11 9

115 Hong Bin洪斌



Grade Two Class A

2009.11 13

116 Chen Wei陈维


2008.3 15 Between 50 and 75



CCB

117 Li Ruogu李若谷



2008.3 9

118 Xu Yingjia徐迎佳



2008.3 10

119 Chen Yang陈阳



Grade Three Class A

2008.3 12

120 Zhou Hua周华



2008.3 12

121 Xu Zuojun许左隽


Shanghai No.9 Hospial Grade Three Class A

2008.3 13

122 Yin Zhaofang殷兆芳



2008.3 11

123 Xian Yuqiong鲜玉琼



2008.3 13

124 Shi Jia施佳



Grade Two Class A

2009.11 8

125 Wang Weiqing汪蔚青



Grade Two Class A

2009.11 13

126 Feng Liuliu冯六六

Male Chief physician Shanghai Yangpu District Shidong Hospial

Grade Two Class A

2009.11 13

127 Xu Renxuan徐任璇

Female Chief physician Shanghai Yangpu District Antu Hospial

Grade Two Class A

2009.11 14

128 Qing Qingyuan蒋庆渊


Shanghai Pudong District Nanhui Central Hospial

Grade Two Class A

2009.11 10

129 Yu Qiang余强


Shanghai Minhang District Central Hospial

Grade Two Class A

2009.11 13

130 Ou Yangping欧阳平

Male Chief physician Shanghai Songjiang District Central Hospial

Grade Two Class A

2009.11 13

131 Zhang Zheng张政



Grade Two Class A

2009.11 5

132 Chen Wei陈伟


Shanghai Yangpu District Shidong Hospial

Grade Two Class A

2009.11 12

133 Guan Shaofeng关韶峰



2009.11 8

134 Zhang Xumin张旭敏



2008.3 10

135 Wang Tiansong王天松



2008.3 11

136 Lai Yan来晏



2009.11 7

137 Cui Song崔松


Shanghai Shuguang Hospial Grade Three Class A

2008.3 10

138 He Yan何燕

Female Chief physician Shanghai Longhua Hospial Grade Three Class A

2008.3 13

139 Xu Jianzhong许建忠



2009.11 8

140 Zhu Shuxian朱淑贤


Shanghai No.5 Hospial Grade Three Class B

2009.11 10

141 Zhang Liwei张丽葳



2008.3 11

142 Zhao Xingxiang赵星祥

Male Chief physician Shanghai Jing’an District Central Hospial

Grade Two Class A

2009.11 10

143 Zhu Wenhao朱文洁

Female Chief physician Shanghai Changning District Central Hospial

Grade Two Class A

2009.11 13

144 Lv Liyou吕立友

Male Chief physician Shanghai Changning District Tongren Hospital

Grade Two Class A

2009.11 14



CCB

145 Wang Dongyi王东毅



Grade Two Class A

2009.11 12

146 Liao Minlei廖敏蕾


Baoshan Branch, Shanghai No. 1 Hospial

Grade Two Class A

2009.11 12

147 Yin Guizhi尹桂芝


Shanghai Minhang District Central Hospial

Grade Two Class A

2009.11 7

148 Jiang Lisheng江立生



2011.5 6

149 Zhang Yang张阳



2008.3 8

150 Shi Chunzhi史春志



2009.11 7

151 Fan Li范例



2009.11 5

152 Chen Jun陈军

Female Doctor-in-charge

Shanghai Yangpu District Antu Hospial

Grade Two Class A

2009.11 5

153 Huang Ying黄瑛


Shanghai Pudong District People’s Hospial

Grade Two Class A

2009.11 10

* Ranked by the yearly PCI procedure volume only** Asking for the PCI procedure volume for each cardiologist, please email us.

Medical insuarance for cardiac products in China(Source: China Cardiovascular Business)

Note: China’s medical insurance scheme consists of urban employee basic medical insurance (UEBMI), urban employee basic medical

insurance (URBMI) and new rural cooperative medical insurance (NRCMI).

Province CityPolicy

effective time

ProductCap price for

reimbursement

Applicable insurance

scheme

Reimbursement percentage

(%)

Self-paid percentage for employee (%)

Reimbursement percentage

(%)

Self-paid percentage for

retiree (%)Beijing Beijing 2012.05.01 Single-chamber pacemaker 16800 NRCMI Not

applicableNot

applicableNot

applicableNot

applicableBeijing Beijing 2008.07.01 Single-chamber pacemaker 16800 UEBMI, URBMI 70% 30% 60% 40%Beijing Beijing 2010.09.01 Single-chamber pacemaker 25200 UEBMI, URBMI 70% 30% 60% 40%Beijing Beijing 2013.01.01 Single-chamber pacemaker 25200 UEBMI, URBMI 70% 30% 70% 30%Beijing Beijing 2012.05.01 Temporary pacemaker 7200 NRCMI Not

applicableNot

applicableNot

applicableNot

applicableBeijing Beijing 2008.07.01 Temporary pacemaker 7200 UEBMI, URBMI 70% 30% 60% 40%Beijing Beijing 2010.09.01 Temporary pacemaker 10800 UEBMI, URBMI 70% 30% 60% 40%Beijing Beijing 2013.01.01 Temporary pacemaker 10800 UEBMI, URBMI 70% 30% 70% 30%Beijing Beijing 2008.07.01 ICD 21600 UEBMI, URBMI 70% 30% 60% 40%Beijing Beijing 2010.09.01 ICD 32400 UEBMI, URBMI 70% 30% 60% 40%Beijing Beijing 2013.01.01 ICD 32400 UEBMI, URBMI 70% 30% 70% 30%Beijing Beijing 2012.05.01 Dual-chamber pacemaker 21600 NRCMI Not

applicableNot

applicableNot

applicableNot

applicableBeijing Beijing 2008.07.01 Dual-chamber pacemaker 21600 UEBMI, URBMI 70% 30% 60% 40%Beijing Beijing 2010.09.01 Dual-chamber pacemaker 32400 UEBMI, URBMI 70% 30% 60% 40%Beijing Beijing 2013.01.01 Dual-chamber pacemaker 32400 UEBMI, URBMI 70% 30% 70% 30%Shanghai Shanghai 2009.12.15 Temporary cardiac pacemaker

electrode25000 UEBMI,

URBMI,NRCMI85% 15% 92% 8%

Shanghai Shanghai 2009.12.15 Pacemaker (ICD) 25000 UEBMI, URBMI,NRCMI

85% 15% 92% 8%

Shanghai Shanghai 2009.12.15 Cardiac pacemaker 25000 UEBMI, URBMI,NRCMI

85% 15% 92% 8%

Shanghai Shanghai 2009.12.15 Aneurysm clip 3000 UEBMI, URBMI,NRCMI

85% 15% 92% 8%



CCB

Shanghai Shanghai 2009.12.15 Needle casing 2000 UEBMI, URBMI,NRCMI

85% 15% 92% 8%

Shanghai Shanghai 2009.12.15 Non-vascular Interventional catheter, wire

1000 UEBMI, URBMI,NRCMI

85% 15% 92% 8%

Shanghai Shanghai 2009.12.15 Abdominal aorta stent 12000 UEBMI, URBMI,NRCMI

85% 15% 92% 8%

Shanghai Shanghai 2009.12.15 Coronary stent 10000 UEBMI, URBMI,NRCMI

85% 15% 92% 8%

Shanghai Shanghai 2009.12.15 Mechanical valve prosthesis 25000 UEBMI, URBMI,NRCMI

85% 15% 92% 8%

Shanghai Shanghai 2009.12.15 Float catheter 2600 UEBMI, URBMI,NRCMI

85% 15% 92% 8%

Shanghai Shanghai 2009.12.15 External counter pulsation airbag device


85% 15% 92% 8%

Shanghai Shanghai 2009.12.15 artificial mesh 25000 UEBMI, URBMI,NRCMI

85% 15% 92% 8%

Shanghai Shanghai 2009.12.15 RFCA catheter 2000 UEBMI, URBMI,NRCMI

85% 15% 92% 8%

Shanghai Shanghai 2009.12.15 Biovalve 25000 UEBMI, URBMI,NRCMI

85% 15% 92% 8%

Shanghai Shanghai 2009.12.15 Cardiac patching materials 3000 UEBMI, URBMI,NRCMI

85% 15% 92% 8%

Shanghai Shanghai 2009.12.15 Thoracic aorta stent 12000 UEBMI, URBMI,NRCMI

85% 15% 92% 8%

Shanghai Shanghai 2009.12.15 Vascular interventional catheter, wire


85% 15% 92% 8%

Shanghai Shanghai 2009.12.15 vascular stent 12000 UEBMI, URBMI,NRCMI

85% 15% 92% 8%

Shanghai Shanghai 2009.12.15 RFCA catheter 2600 UEBMI, URBMI,NRCMI

85% 15% 92% 8%

Shanghai Shanghai 2009.12.15 Puncture needle 2000 UEBMI, URBMI,NRCMI

85% 15% 92% 8%

Guangdong Dongguan 2013.05.01 Test tube 7000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Diagnostic catheter 4000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Test tube 5000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Test tube 5000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Radiofrequency ablation needle 7500 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Ablation catheter 8000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 ICD electrode 500 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Pacemaker electrode, wire 2000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 CRT/CRTD/ICD/DDDR 9000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 ICD 9000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 PTA balloon 2500 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 PTA balloon dilating catheter 2500 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 PTCA balloon 2500 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 PTCA balloon dilating catheter 1500 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Wire 8000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Sheath 1500 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Catheter sheath 1200 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Wire, catheter 800 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Guiding wire, catheter 800 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Guiding sheath 1000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Aneurysm clip 2500 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Mitral valve balloon 6000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Mitral valve balloon dilating catheter 8000 UEBMI, URBMI 70% 30% 70% 30%



CCB

Guangdong Dongguan 2013.05.01 Pulmonary artery balloon catheter 4000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 pulmonary artery balloon 6000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Blocking balloon catheter system 8000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Abdominal aorta stent 40000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Coronary intravascular ultrasound

catheter8000 UEBMI, URBMI 70% 30% 70% 30%

Guangdong Dongguan 2013.05.01 Coronary stent 8000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Coronary artery balloon 3000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Coronary artery balloon dilating

catheter 1500 UEBMI, URBMI 70% 30% 70% 30%

Guangdong Dongguan 2013.05.01 Coronary artery stent 15000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Metal stent 8000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Carotid artery stent 8000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Spring coil 5000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Emulsion balloon 800 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 IVCF 7000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Intracranial vascular stent 8000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Balloon 1000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Balloon 2500 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Balloon pressure pump 5500 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Balloon catheter 1500 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Tricuspid valve balloon 8000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Kidney stent 8000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Spring coil 800 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Embolism particles 1000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Peripheral Balloon dilating catheter 4000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Peripheral balloon 2000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Peripheral vascular stent 8000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Microguide wire, Micro catheter 2000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 thoracic aorta stent 40000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Vascular sheath 800 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Vascular distal protection device 8000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Thrombus aspiration catheter 6000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Pressure pump 5000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Pressure sensor device 500 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Pressure extension tube 500 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Drug stent 8000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Permanent vena cava filter 7000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Radiography catheter 500 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Stent balloon catheter 3000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Intra-aortic balloon catheter 6000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Vertebral Balloon catheter 5000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Dongguan 2013.05.01 Vertebral Balloon 8000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Foshan 2013.07.01 pacemaker 35000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Foshan 2013.07.01 coronary artery stent 14000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Foshan 2013.07.01 Aortic stent 76000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Guangzhou 2010.10.01 Single-chamber pacemaker N/A UEBMI, URBMI 72% 28% 75% 25%Guangdong Guangzhou 2010.10.01 Temporary pacemaker N/A UEBMI, URBMI 72% 28% 75% 25%Guangdong Guangzhou 2010.10.01 ICD N/A UEBMI, URBMI 72% 28% 75% 25%Guangdong Guangzhou 2010.10.01 Dual-chamber pacemaker N/A UEBMI, URBMI 72% 28% 75% 25%Guangdong Heyuan 2012.01.01 Cardiac radiofrequency ablation

catheter (domestic)10000 UEBMI 50% 50% 50% 50%

Guangdong Heyuan 2012.01.01 Cardiac radiofrequency ablation catheter (imported)

10000 UEBMI 65% 35% 65% 35%



CCB

Guangdong Heyuan 2012.01.01 Single-chamber pacemaker (domestic)

17650 UEBMI 50% 50% 50% 50%

Guangdong Heyuan 2012.01.01 Single-chamber pacemaker (imported)

17650 UEBMI 65% 35% 65% 35%

Guangdong Heyuan 2012.01.01 Dual-chamber pacemaker (domestic)

38000 UEBMI 50% 50% 50% 50%

Guangdong Heyuan 2012.01.01 Dual-chamber pacemaker (imported)

38000 UEBMI 65% 35% 65% 35%

Guangdong Heyuan 2012.01.01 mitral valve balloon(domestic) 13250 UEBMI 50% 50% 50% 50%Guangdong Heyuan 2012.01.01 mitral valve balloon(imported) 13250 UEBMI 65% 35% 65% 35%Guangdong Heyuan 2012.01.01 Coronary arter y stent(domestic) 11730 UEBMI 50% 50% 50% 50%Guangdong Heyuan 2012.01.01 Coronary artery stent(imported) 11730 UEBMI 65% 35% 65% 35%Guangdong Heyuan 2012.01.01 Iliac artery stent(domestic) 18000 UEBMI 50% 50% 50% 50%Guangdong Heyuan 2012.01.01 Iliac artery stent(imported) 18000 UEBMI 65% 35% 65% 35%Guangdong Heyuan 2012.01.01 Filter(domestic) 19750 UEBMI 50% 50% 50% 50%Guangdong Heyuan 2012.01.01 Filter(imported) 19750 UEBMI 65% 35% 65% 35%Guangdong Heyuan 2012.01.01 Balloon(domestic) 4150 UEBMI 50% 50% 50% 50%Guangdong Heyuan 2012.01.01 Balloon(imported) 4150 UEBMI 65% 35% 65% 35%Guangdong Heyuan 2012.01.01 Thoracic aorta stent(domestic) 10000 UEBMI 50% 50% 50% 50%Guangdong Heyuan 2012.01.01 Thoracic aorta stent(imported) 10000 UEBMI 65% 35% 65% 35%Guangdong Heyuan 2012.01.01 Vascular stent(domestic) 1750 UEBMI 50% 50% 50% 50%Guangdong Heyuan 2012.01.01 Vascular stent(imported) 1750 UEBMI 65% 35% 65% 35%Guangdong Huizhou 2009.07.23 Cardiac radiofrequency ablation

catheter10000 UEBMI 45% 55% 45% 55%

Guangdong Huizhou 2009.07.23 Single-chamber pacemaker 17650 UEBMI 45% 55% 45% 55%Guangdong Huizhou 2009.07.23 Dual-chamber pacemaker 38000 UEBMI 45% 55% 45% 55%Guangdong Huizhou 2009.07.23 Mitral valve balloon 13250 UEBMI 45% 55% 45% 55%Guangdong Huizhou 2009.07.23 Coronary artery stent 11730 UEBMI 45% 55% 45% 55%Guangdong Huizhou 2009.07.23 Iliac artery stent 18000 UEBMI 45% 55% 45% 55%Guangdong Huizhou 2009.07.23 Filter 19750 UEBMI 45% 55% 45% 55%Guangdong Huizhou 2009.07.23 Balloon 4150 UEBMI 45% 55% 45% 55%Guangdong Huizhou 2009.07.23 Thoracic aorta stent 10000 UEBMI 45% 55% 45% 55%Guangdong Huizhou 2009.07.23 Vascular stent 1750 UEBMI 45% 55% 45% 55%Guangdong Jiangmen 2011.01.01 Cardiac radiofrequency ablation

catheter10000 UEBMI,

URBMI+NRCMI85% 15% 85% 15%

Guangdong Jiangmen 2011.01.01 Single-chamber pacemaker 17650 UEBMI, URBMI+NRCMI

85% 15% 85% 15%

Guangdong Jiangmen 2011.01.01 Dual-chamber pacemaker 38000 UEBMI, URBMI+NRCMI

85% 15% 85% 15%

Guangdong Jiangmen 2011.01.01 Mitral valve balloon 13250 UEBMI, URBMI+NRCMI

85% 15% 85% 15%

Guangdong Jiangmen 2011.01.01 Coronary artery stent 11730 UEBMI, URBMI+NRCMI

85% 15% 85% 15%

Guangdong Jiangmen 2011.01.01 Iliac artery stent 18000 UEBMI, URBMI+NRCMI

85% 15% 85% 15%

Guangdong Jiangmen 2011.01.01 Filter 19750 UEBMI, URBMI+NRCMI

85% 15% 85% 15%

Guangdong Jiangmen 2011.01.01 Balloon 4150 UEBMI, URBMI+NRCMI

85% 15% 85% 15%

Guangdong Jiangmen 2011.01.01 Thoracic aorta stent 10000 UEBMI, URBMI+NRCMI

85% 15% 85% 15%

Guangdong Jiangmen 2011.01.01 Vascular stent 1750 UEBMI, URBMI+NRCMI

85% 15% 85% 15%

Guangdong Meizhou 2012.01.01 Test catheter 10000 UEBMI, URBMI 80% 20% 80% 20%



CCB

Guangdong Meizhou 2012.01.01 Single-chamber pacemaker 30000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Three chamber cardiac pacemaker 90000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Dual-chamber pacemaker 80000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 ICD 90000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 PTA balloon dilating catheter 4500 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Mitral valve balloon 12000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 mitral valve balloon dilating

catheter 12000 UEBMI, URBMI 80% 20% 80% 20%

Guangdong Meizhou 2012.01.01 Pulmonary artery balloon catheter 8000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Pulmonary artery balloon 10000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Blocking balloon catheter 12000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Abdominal aorta stent 85000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Coronary ultrasound catheter 14000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Coronary stent 18000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Coronary artery balloon 4500 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Coronary artery stent 27000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Carotid artery stent 14000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Filter 12000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Intracranial vascular stent 20000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Tricuspid valve Balloon 13000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Peripheral balloon dilating catheter 5500 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Microguide wire, Micro catheter 3000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Thoracic aorta stent 85000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Drug stent 16000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Permanent vena cava filter 15000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Stent balloon catheter 4500 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Intra-aortic balloon catheter 10000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Vertebral balloon catheter 10000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Meizhou 2012.01.01 Vertebral Balloon 13000 UEBMI, URBMI 80% 20% 80% 20%Guangdong Shantou 2001.06.15 Cardiac radiofrequency ablation


Guangdong Shantou 2001.06.15 Single-chamber pacemaker 17650 UEBMI, URBMI 70% 30% 70% 30%Guangdong Shantou 2001.06.15 Dual-chamber pacemaker 38000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Shantou 2001.06.15 Mitral valve balloon 13250 UEBMI, URBMI 70% 30% 70% 30%Guangdong Shantou 2001.06.15 Coronary artery stent 11730 UEBMI, URBMI 70% 30% 70% 30%Guangdong Shantou 2001.06.15 Iliac artery stent 18000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Shantou 2001.06.15 Filter 19750 UEBMI, URBMI 70% 30% 70% 30%Guangdong Shantou 2001.06.15 Balloon 4150 UEBMI, URBMI 70% 30% 70% 30%Guangdong Shantou 2001.06.15 Thoracic aorta stent 10000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Shantou 2001.06.15 Vascular stent 1750 UEBMI, URBMI 70% 30% 70% 30%Guangdong Shenzhen 2008.10.13 Imported catheter 15000 UEBMI, URBMI 60% 40% 60% 40%Guangdong Shenzhen 2008.10.13 Domestic pacemaker 27900 UEBMI, URBMI 90% 10% 90% 10%Guangdong Shenzhen 2008.10.13 Imported valve 15499 UEBMI, URBMI 60% 40% 60% 40%Guangdong Shenzhen 2008.10.13 Imported pacemaker 52800 UEBMI, URBMI 60% 40% 60% 40%Guangdong Shenzhen 2008.10.13 Occluder 18000 UEBMI, URBMI 60% 40% 60% 40%Guangdong Shenzhen 2008.10.13 Domestic endovascular catheter 1800 UEBMI, URBMI 90% 10% 90% 10%Guangdong Shenzhen 2008.10.13 Domestic endovascular balloon 9749 UEBMI, URBMI 90% 10% 90% 10%Guangdong Shenzhen 2008.10.13 domestic endovascular stent 24000 UEBMI, URBMI 90% 10% 90% 10%Guangdong Shenzhen 2008.10.13 Imported abdominal aorta stent 75000 UEBMI, URBMI 60% 40% 60% 40%Guangdong Shenzhen 2008.10.13 Imported spring coil 9000 UEBMI, URBMI 60% 40% 60% 40%Guangdong Shenzhen 2008.10.13 Imported cerebrovascular catheter 5400 UEBMI, URBMI 60% 40% 60% 40%Guangdong Shenzhen 2008.10.13 Imported cerebrovascular balloon 12000 UEBMI, URBMI 60% 40% 60% 40%Guangdong Shenzhen 2008.10.13 Imported cerebrovascular stent 18000 UEBMI, URBMI 60% 40% 60% 40%Guangdong Shenzhen 2008.10.13 Imported endovascular catheter 1849 UEBMI, URBMI 60% 40% 60% 40%



CCB

Guangdong Shenzhen 2008.10.13 Imported endovascular balloon 6850 UEBMI, URBMI 60% 40% 60% 40%Guangdong Shenzhen 2008.10.13 Imported endovascular stent 22099 UEBMI, URBMI 60% 40% 60% 40%Guangdong Yunfu 2012.12.26 Cardiac radiofrequency ablation


Guangdong Yunfu 2012.12.26 Single-chamber pacemaker 17650 UEBMI, URBMI 50% 50% 50% 50%Guangdong Yunfu 2012.12.26 Dual-chamber pacemaker 38000 UEBMI, URBMI 50% 50% 50% 50%Guangdong Yunfu 2012.12.26 Mitral valveBalloon 13250 UEBMI, URBMI 50% 50% 50% 50%Guangdong Yunfu 2012.12.26 Coronary arterystent 11730 UEBMI, URBMI 50% 50% 50% 50%Guangdong Yunfu 2012.12.26 Iliac artery stent 18000 UEBMI, URBMI 50% 50% 50% 50%Guangdong Yunfu 2012.12.26 Filter 19750 UEBMI, URBMI 50% 50% 50% 50%Guangdong Yunfu 2012.12.26 Balloon 4150 UEBMI, URBMI 50% 50% 50% 50%Guangdong Yunfu 2012.12.26 Thoracic aorta stent 10000 UEBMI, URBMI 50% 50% 50% 50%Guangdong Yunfu 2012.12.26 Vascular stent 1750 UEBMI, URBMI 50% 50% 50% 50%Guangdong Zhongshan 2010.07.01 Test tube 10000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Single-chamber pacemaker 30000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Three chamber cardiac pacemaker 90000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Dual-chamber pacemaker 80000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 ICD 90000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 PTA balloon dilating catheter 4500 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Mitral valve balloon 12000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Mitral valve balloon dilating catheter 12000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Pulmonary artery dilating balloon 8000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Pulmonary artery balloon 10000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Blocking balloon catheter 12000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Abdominal aorta stent 85000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Coronary intravascular

ultrasound catheter14000 UEBMI, URBMI 70% 30% 70% 30%

Guangdong Zhongshan 2010.07.01 Coronary stent 18000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Coronary artery Balloon 4500 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 coronary artery stent 27000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Carotid artery stent 14000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Filter 12000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Intracranial vascular stent 20000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Tricuspid valve balloon 13000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Peripheral Balloon dilating catheter 5500 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Microwire, Micro catheter 3000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 thoracic aorta stent 85000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Drug stent 16000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Permanent vena cava filter 15000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Stent balloon 4500 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Intra aortic balloon catheter 10000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Vertebral dilating balloon 10000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhongshan 2010.07.01 Vertebral balloon 13000 UEBMI, URBMI 70% 30% 70% 30%Guangdong Zhuhai 2010.05.01 Cardiac radiofrequency ablation


Guangdong Zhuhai 2010.05.01 Single-chamber pacemaker 17650 UEBMI, URBMI 60% 40% 60% 40%Guangdong Zhuhai 2010.05.01 Dual-chamber pacemaker 38000 UEBMI, URBMI 60% 40% 60% 40%Guangdong Zhuhai 2010.05.01 Mitral valve balloon 13250 UEBMI, URBMI 60% 40% 60% 40%Guangdong Zhuhai 2010.05.01 Coronary artery stent 11730 UEBMI, URBMI 60% 40% 60% 40%Guangdong Zhuhai 2010.05.01 Iliac artery stent 18000 UEBMI, URBMI 60% 40% 60% 40%Guangdong Zhuhai 2010.05.01 Filter 19750 UEBMI, URBMI 60% 40% 60% 40%Guangdong Zhuhai 2010.05.01 Balloon 4150 UEBMI, URBMI 60% 40% 60% 40%Guangdong Zhuhai 2010.05.01 Thoracic aorta stent 10000 UEBMI, URBMI 60% 40% 60% 40%Guangdong Zhuhai 2010.05.01 Vascular stent 1750 UEBMI, URBMI 60% 40% 60% 40%



CCB

Top 100 hospitals by RFCA procedure volume in China (2013) *(Source: China Cardiovascular Business)

Hospital Grade Category Province CityHospital

beds

Cardiology department

beds

RFCA cardiologists

RFCA procedure volume in

2013Fuwai Hospital Grade Three Class A Cardiac hospital Beijing Beijing 659 184 18 3680Wuhan Asia Heart Hospital Grade Three Class A Cardiac hospital Hubei Wuhan 500 100 8 2350Shanghai Chest Hospial Grade Three Class A Chest hospital Shanghai Shanghai 676 50 8 2150Guangdong People’s Hospital Grade Three Class A General hospital Guangdong Guangzhou 2053 150 8 2050Beijing Anzhen Hospital Grade Three Class A Cardiac hospital Beijing Beijing 937 136 14 1880West China Hospital Grade Three Class A General hospital Sichuan Chengdu 4091 101 6 1575Zhongshan Hospial Affiliated to Fudan University

Grade Three Class A General hospital Shanghai Shanghai 1530 190 7 1500

Jiangsu People’s Hospital Grade Three Class A General hospital Jiangsu Nanjing 1866 74 8 1230First Hospital Affilated to Zhejiaing University

Grade Three Class A General hospital Zhejiang Hangzhou 1984 80 7 948

Hubei People’s Hospital Grade Three Class A General hospital Hubei Wuhan 1300 80 4 924Shaoyifu Hospital Affilated to Zhejiaing University


Zhengzhou No. 7 People’s Hospital Grade Three Class A Cardiac hospital Henan Zhengzhou 110 50 3 868Second Hospital Affilated to Harbin Medical University

Grade Three Class A General hospital Heilongjiang Harbin 1681 170 4 730

First Hospital Affilated to Zhengzhou University

Grade Three Class A General hospital Henan Zhengzhou 1678 100 6 720

Central South China University Xiangya Second Hospital

Grade Three Class A General hospital Hunan Changsha 2426 85 4 675

Lanzhou UniversityFirst Hospital Grade Three Class A General hospital Gansu Lanzhou 1049 84 7 636Tianjin Chest hospital Grade Three Class A Chest hospital Tianjin Tianjin 449 180 5 625Beijing Chaoyang Hospital Grade Three Class A General hospital Beijing Beijing 1506 135 6 620First Hospital A ffiliated to Guangxi Medical University

Grade Three Class A General hospital Guangxi Nanning 2447 85 4 580

Central South China University Xiangya Hospital


Zhongshan Hospital Affiliated to Xiamen University

Grade Three Class A General hospital Fujian Xiamen 1087 60 4 570

Second Hospital Affiliated to Nanchang University

Grade Three Class A General hospital Jiangxi Nanchang 787 80 6 559

First Hospital Affiliated to Dalian Medical University

Grade Three Class A General hospital Liaoning Dalian 1599 83 4 542

First Hospital Affiliated to Xi’an Jiaotong University

Grade Three Class A General hospital Shaanxi Xi’an 1502 78 6 540

First Hospital Affiliated to Harbin Medical University


Second Hospital Affiliated to Zhejiang University


Jilin University Second Hospital Grade Three Class A General hospital Jilin Changchun 1159 80 5 530Shanghai Xinhua Hospital Grade Three Class A General hospital Shanghai Shanghai 1178 70 4 518First Hospital Affiliated to China Medical University

Grade Three Class A General hospital Liaoning Shenyang 1436 93 4 495



CCB

Shengjing Hospital Affiliated to China Medical University

Grade Three Class A General hospital Liaoning Shenyang 2853 83 4 477

Shanghai No. 1 Hospial Grade Three Class A General hospital Shanghai Shanghai 1642 110 5 470First Hospital Affiliated to Xinjiang Medical University

Grade Three Class A General hospital Xijiang Urumchi 1933 20 5 470

Henan People’s Hospital Grade Three Class A General hospital Henan Zhengzhou 1877 35 5 455First Hospital Affiliated toChongqing Medical University

Grade Three Class A General hospital Chongqing Chongqing 1700 110 6 455

Jilin University First Hospital Grade Three Class A General hospital Jilin Changchun 1240 90 4 440First Hospital Affiliated to Kunming Medical University

Grade Three Class A General hospital Yunnan Kunming 1301 100 5 435

First Hospital Affiliated to Zhongshan University

Grade Three Class A General hospital Guangdong Guangzhou 2094 45 5 432

Union Hospital Affiliated to Huazhong University of Science and Technology

Grade Three Class A General hospital Hubei Wuhan 1613 50 5 432

Fourth Hospital Affiliated to Harbin Medical University


Nanjing GulouHospital Grade Three Class A General hospital Jiangsu Nanjing 1383 90 4 425Wuxi People’s Hospital Grade Three Class A General hospital Jiangsu Wuxi 800 83 2 420Hebei People’s Hospital Grade Three Class A General hospital Hebei Shijiazhuang 931 90 4 415Beijing University People’s Hospital Grade Three Class A General hospital Beijing Beijing 1219 100 6 405First Hospital Affiliated to Suzhou University

Grade Three Class A General hospital Jiangsu Suzhou 1408 75 4 402

Jiangxi People’s Hospital Grade Three Class A General hospital Jiangxi Nanchang 906 40 4 395Shandong Provincial Hospital Grade Three Class A General hospital Shandong Jinan 1749 32 5 395Shandong University Qilu Hospital Grade Three Class A General hospital Shandong Jinan 1598 50 4 390Fujian Provincial Hospital Grade Three Class A General hospital Fujian Fuzhou 1061 120 3 385Shanghai Ruijin Hospial Grade Three Class A General hospital Shanghai Shanghai 1653 100 5 384Shanghai Renji Hospial Grade Three Class A General hospital Shanghai Shanghai 1528 98 4 375Nanjing FirstHospital Grade Three Class A General hospital Jiangsu Nanjing 850 85 3 353South Medical University Southern Hospital


Hebei Medical University Second Hospital

Grade Three Class A General hospital Hebei Shijiazhuang 1327 80 4 350

Shanxin Cardiovascular diseases Hospital

Grade Three Class A Cardiac hospital Shanxi Taiyuan 150 90 3 350

Beijing Union Hospital Grade Three Class A General hospital Beijing Beijing 1808 32 6 346Tongji Hospital Affiliated to Huazhong University of Science and Technology

Grade Three Class A General hospital Hubei Wuhan 2016 40 4 338

Qingdao University Affiliated to Hospital

Grade Three Class A General hospital Shandong Qingdao 1233 80 5 325

Sichuan People’s Hospital Grade Three Class A General hospital Sichuan Chengdu 1803 110 4 324Anhui Provincial Hospital Grade Three Class A General hospital Anhui Hefei 1401 65 5 318Hunan People’s Hospital Grade Three Class A General hospital Hunan Changsha 844 54 4 315Jining First People’s Hospital Grade Three Class A General hospital Shandong Jining 1052 90 4 313Tianjin Medical University Second Hospital

Grade Three Class A General hospital Tianjin Tianjin 734 88 3 301

Tianjin Teda International Cardiovascular Hospital

Grade Three Class A Cardiac hospital Tianjin Tianjin 157 68 3 298

Shenzhen Sun Yet-sen Cardiovascular Hospital

Grade Three Class A Cardiac hospital Guangdong Shenzhen 120 65 3 297



CCB

Henan Chest hospital Grade Three Class A Chest hospital Henan Zhengzhou 507 41 4 297Xuzhou Central Hospital Grade Three Class A General hospital Jiangsu Xuzhou 1200 130 3 285Tianjin Medical University General Hospital

Grade Three Class A General hospital Tianjin Tianjin 1600 94 3 280

Frist Hospital Affiliated to Wenzhou Medical College

Grade Three Class A General hospital Zhejiang Wenzhou 1496 50 2 275

Fujian Medical University Affiliated to Union Hospital

Grade Three Class A General hospital Fujian Fuzhou 1334 100 5 262

Anhui Medical University First Hospital Affiliated to

Grade Three Class A General hospital Anhui Hefei 1822 55 4 261

First Hospital Affiliated to Henan Technology University

Grade Three Class A General hospital Henan Luoyang 1151 70 3 260

Central South China University Xiangya Third Hospital


Zhejiang People’s Hospital Grade Three Class A General hospital Zhejiang Hangzhou 1100 58 6 252Guangxi People’s Hospital Grade Three Class A General hospital Guangxi Nanning 1431 85 3 250Beijing University Thrid Hospital Grade Three Class A General hospital Beijing Beijing 1183 78 5 248Beijing Youyi Hospital Grade Three Class A General hospital Beijing Beijing 892 75 4 248Shanghai East Hospial Grade Three Class A General hospital Shanghai Shanghai 753 60 1 246Ningxia Medical University General Hospital

Grade Three Class A General hospital Ningxia Yinchuan 1215 58 4 245

Shanxi Medical University First Hospital Grade Three Class A General hospital Shanxi Taiyuan 928 70 4 245Chongqing Medical University Second Hospital Affiliated to

Grade Three Class A General hospital Chongqing Chongqing 943 48 5 243

Ningbo First Hospital Grade Three Class A General hospital Zhejiang Ningbo 1004 50 5 240Subei People’s Hospital Grade Three Class A General hospital Jiangsu Yangzhou 1176 63 4 235Hebei Medical University First Hospital Grade Three Class A General hospital Hebei Shijiazhuang 855 60 3 230Tangshan Workers Hospital Grade Three Class A General hospital Hebei Tangshan 1249 60 3 230Second Hospital Affiliated to Xi’an Jiaotong University

Grade Three Class A General hospital Shaanxi Xi’an 872 70 4 230

Shandong Qianfoshan Hospital Grade Three Class A General hospital Shandong Jinan 759 40 3 226Kunming Yanan Hospital Grade Three Class A General hospital Yunnan Kunming 706 100 2 226Second Hospital Affiliated to Zhongshan University


Guizhou People’s Hospital Grade Three Class A General hospital Guizhou Guiyanga 1468 80 2 225Wuxi Second People’s Hospital Grade Three Class A General hospital Jiangsu Wuxi 650 97 4 225Second Hospital Affiliated to Wenzhou Medical College

Grade Three Class A General hospital Zhejiang Wenzhou 1558 100 4 223

Lanzhou University Second Hospital Grade Three Class A General hospital Gansu Lanzhou 800 40 2 220Xijiang People’s Hospital Grade Three Class A General hospital Xijiang Urumchi 1556 80 4 220Beijing Tongren Hospital Grade Three Class A General hospital Beijing Beijing 1530 68 2 216Shanghai No. 10 Hospial Grade Three Class A General hospital Shanghai Shanghai 785 80 3 216First Hospital Affiliated to Fujian Medical University

Grade Three Class A General hospital Fujian Fuzhou 1409 55 5 215

Foshan First People’s Hospital Grade Three Class A General hospital Guangdong Foshan 1443 65 1 215Yantai Liuhuangding Hospital Grade Three Class A General hospital Shandong Yantai 1607 100 3 215Zhejiang Hospital Grade Three Class A General hospital Zhejiang Hangzhou 500 41 4 215Liaoning People’s Hospital Grade Three Class A General hospital Liaoning Shenyang 550 139 4 212

* RFCA short for radiofrequency catheter ablation



CCB

Transmedia CardioChina Service

CardioChina (cardiochina.com) is a service from Transmedia Healthcare, a China-based business intelligence provider for the global life sciences industry.

CardioChina tracks and analyzes the regulatory, commercial and technological developments of the cardiovascular world in China through its established portfolio of data products and services.

China Cardiovascular Business (CCB)

CCB is a monthly newsletter that provides China-focused cardiovascular business news, regulatory review, market insights, KOL profiling & ranking as well as procedure tracking data. The newsletter is edited by a panel of cardiologists working at China’s top-notch cardiovascular disease hospitals.

Data Solutions

CardioChina tracks and monitors key cardiovascular hospitals, leading cardiologists (especially interventional cardiologists) and major cardio procedures. We offer in-depth data solutions covering six segments: Percutaneous Coronary Intervention (PCI), Cardiac Pacemaker, CABG , EP/RFCA, Coronary Angiography(CAG), Cardiac Electrophysiology (EP).

Our data solutions include:

China Hospital-specific Procedure Tracking and Audit

Procedure-capable Chinese Hospitals Mapping and Ranking

Procedure-capable Chinese Interventional Cardiologists Mapping and Ranking

CardioPower: Influencers and Followers of Chinese Cardiologists

Consulting & Training Services

CardioChina offer emerging Chinese cardiologists training services through courses, seminars & conferences.

We also offer networking opportunities through editing and publishing books or journals in translation, and organizing seminars and conferences.

Please contact us for more information on how Transmedia Cardiovascular Service can help your organization with our trusted, customized services.

Transmedia Healthcare Data Group

Beijing北京传红：Suite 916, 9/F, Xu Jie Office Building, Chaoyang District 100022

T: (8610) 87518435 F: (8610) 87518435

Shanghai上海传科：Suite 2002, No.168 Yude Rd., Xuhui District, Shanghai 200030

T:(8621)33682001 F: (8621)33682001

Chongqing重庆传美：C3-4-6, California Gardens, Yubei Dist., Chongqing 401147

T: (8623) 67035795 F: (8623) 67036286

CCB2-1

Documents

pci treatment

pci procedures

pci accessibilitydespite

direct pci

national pci registry

reasonable use of pci

chinas hospitals

china cardiovascular